[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 52 of about 52
1. Mader AM, Patrício FR, Rigueiro MP, Lourenço LG: [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia]. Arq Gastroenterol; 2006 Jul-Sep;43(3):184-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia].
  • [Transliterated title] Estudo clínico-patológico, da proliferação celular e da apoptose no adenocarcinoma gástrico da cárdia.
  • MATERIAL AND METHODS: Forty cases of adenocarcinoma of the cardia were studied between 1988 and 2001, with a minimum clinical follow-up of 3 years.
  • Gender; age, Laurén and Ming histological type, staging, and the presence or absence of intestinal metaplasia, epithelial dysplasia and Helicobacter pylori in the adjacent mucosa were analyzed.
  • For the survival analysis, cases with distant metastasis upon diagnosis were excluded.
  • There was no association with intestinal metaplasia and/or H. pylori.
  • CONCLUSIONS: Adenocarcinoma of the cardia predominated in male adults of mean age 61 years, and the predominant type was diffuse in more advanced stages.
  • Survival in cases of adenocarcinoma of the cardia is still low.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Cardia / pathology. Cell Proliferation. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160232.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


2. Yao T, Utsunomiya T, Oya M, Nishiyama K, Tsuneyoshi M: Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features. World J Gastroenterol; 2006 Apr 28;12(16):2510-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features.
  • AIM: Minimal deviation carcinoma of the uterine cervix, otherwise known as extremely well-differentiated adenocarcinoma (EWDA), is characterized by its benign microscopic appearance in contrast to its aggressive behavior.
  • In order to elucidate the clinicopathological features and biological behavior of the gastric counterpart of EWDA, we, using immunohistochemistry, analyzed nine lesions for the phenotypic expression, proliferative activity, and the expression of oncogene-associated products.
  • METHODS: Clinicopathological features, including pre-operative biopsy diagnosis, were reviewed.
  • Using immunohistochemistry, Ki-67 labeling index and expression of p53 and c-erbB-2 protein in the gastric lesions were detected.
  • RESULT: Locations in the middle or upper third of the stomach and polypoid macroscopic features are characteristic of EWDA of the stomach.
  • All 9 cases of EWDA could be classified into gastric phenotype (5 lesions) and intestinal phenotype (4 lesions).
  • The former resembled gastric foveolar epithelium, mucous neck cells or pyloric glands, but their papillary structures were frequently elongated and the tumor cells and their nuclei were slightly larger and more hyperchromatic compared to normal epithelium.
  • The latter resembled intestinal metaplasia with minimal nuclear atypia and irregular glands; two of these lesions demonstrated complete intestinal phenotype, while two demonstrated incomplete intestinal phenotype.
  • CONCLUSION: Unlike minimal deviation carcinoma of the cervix, these findings suggest that EWDA of the stomach is a lesion of low-grade malignancy.
  • Because of its resemblance to normal gastric mucosa or mucosa with intestinal metaplasia, EWDA is often misdiagnosed.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1994 Apr;91(4):839-48 [7513368.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):511-7 [8129036.001]
  • [Cites] J Histochem Cytochem. 1996 Oct;44(10):1161-6 [8813081.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):345-51 [9520947.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):867-70 [9625834.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1719-29 [10223565.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):104-6 [10393360.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Hum Pathol. 2000 Mar;31(3):279-87 [10746668.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):713-8 [10854531.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):17-26 [11115563.001]
  • [Cites] Histopathology. 2000 Dec;37(6):513-22 [11122433.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):166-70 [11668493.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):80-6 [11823976.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):869-73 [12064010.001]
  • [Cites] Am J Obstet Gynecol. 1975 Apr 1;121(7):971-5 [1115185.001]
  • [Cites] Br J Cancer. 1980 Feb;41(2):209-21 [6989383.001]
  • [Cites] Biochem J. 1980 Nov 1;191(2):645-8 [7016112.001]
  • [Cites] J Exp Med. 1981 Oct 1;154(4):1249-54 [6945392.001]
  • [Cites] Acta Pathol Jpn. 1983 Mar;33(2):395-401 [6869006.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):717-29 [2764221.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] Int J Cancer. 1991 Jan 21;47(2):304-10 [1988372.001]
  • [Cites] Int J Cancer. 1992 Apr 1;50(6):859-62 [1555884.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):384-90 [1353880.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1030-7 [1515980.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):558-62 [1520594.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):641-51 [7678777.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):589-93 [8439509.001]
  • [Cites] J Biol Chem. 1993 Mar 15;268(8):5879-85 [7680650.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):28-36 [8020672.001]
  • (PMID = 16688795.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / MUC6 protein, human; 0 / Mucin-6; 0 / Mucins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC4087982
  •  go-up   go-down


3. Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Iacobuzio-Donahue CA, Maitra A, Ashfaq R, Hustinx S, Heitmiller RE, Choti MA, Lillemoe KD, Cameron JL, Yeo CJ, Schulick RD, Montgomery E: Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol Biomarkers Prev; 2006 Feb;15(2):281-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions.
  • Approximately 23,000 new gastric cancer cases and 12,000 associated deaths occur annually in the United States.
  • Intestinal metaplasia and gastric epithelial dysplasia are precursor lesions to gastric adenocarcinoma, but are not readily detectable clinically, radiographically, or endoscopically.
  • In search of such markers, tissue microarrays were prepared for 133 patients of resected gastric adenocarcinoma.
  • Tissue microarrays contained primary cancer, normal stomach, intestinal metaplasia, and gastric epithelial dysplasia and were probed with antibodies against nine potential markers that were either identified in a database of genes overexpressed in gastric adenocarcinoma or were already of interest to our laboratory: claudin-4, mitogen-activated protein kinase kinase 4 (MKK4), 14-3-3sigma (stratifin), S100A4, mesothelin, fascin, topoisomerase IIalpha, HER-2/neu, and epithelial growth factor receptor.
  • Three markers discriminated gastric adenocarcinoma precursor lesions from normal gastric mucosa.
  • Claudin-4 expression was present in 36 intestinal metaplasia lesions (100%) and 14 gastric epithelial dysplasia lesions (100%), but in only 16 normal stomach samples (15%).
  • MKK4 expression was present in 24 intestinal metaplasia lesions (89%) and 12 gastric epithelial dysplasia lesions (100%), but in only 6 normal stomach samples (8%).
  • Stratifin expression was present in 29 intestinal metaplasia lesions (97%) and 8 gastric epithelial dysplasia lesions (100%), but in only 2 normal stomach samples (3%).
  • Sensitivity and specificity for detection of the precursor lesion intestinal metaplasia were 100% and 85%, respectively, for claudin-4; 89% and 92%, respectively, for MKK4; and 97% and 97%, respectively, for stratifin.
  • In conclusion, claudin-4, MKK4, and stratifin immunolabeling detects precursor lesions of gastric adenocarcinoma that are otherwise clinically, radiographically, and endoscopically inapparent.
  • These findings may prove useful in the diagnosis and therapeutic targeting of gastric adenocarcinoma precursor lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Exonucleases / biosynthesis. MAP Kinase Kinase 4 / biosynthesis. Membrane Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] 14-3-3 Proteins. Aged. Claudin-4. Exoribonucleases. Female. Gene Expression. Humans. Immunohistochemistry. Male. Metaplasia / pathology. Microarray Analysis. Tissue Array Analysis


Advertisement
4. Yap YL, So JB: Gastric adenocarcinoma occurring in a young patient with common variable immunodeficiency syndrome. Singapore Med J; 2009 Jun;50(6):e201-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma occurring in a young patient with common variable immunodeficiency syndrome.
  • Patients with common variable immunodeficiency syndrome (CVID) have an increased risk of gastric adenocarcinoma.
  • We describe a case of gastric adenocarcinoma in a 29-year-old man with CVID.
  • CVID is a predisposing factor for gastric adenocarcinoma.
  • Gastric complaints are common among these patients and should be viewed seriously.
  • Premalignant conditions like chronic atrophic gastritis, intestinal metaplasia and dysplasia require regular endoscopic surveillance in these high-risk patients.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Common Variable Immunodeficiency / complications. Common Variable Immunodeficiency / diagnosis. Stomach Neoplasms / complications. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Disease-Free Survival. Endoscopy. Humans. Male. Pyloric Stenosis / diagnosis. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Common Variable Immunodeficiency.
  • Genetic Alliance. consumer health - Young syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19551296.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


5. Takubo K, Vieth M, Aida J, Sawabe M, Kumagai Y, Hoshihara Y, Arai T: Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. Digestion; 2009;80(4):248-57
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for barrett's adenocarcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia.
  • METHODS: Here we discuss four such important differences: the definition of the esophagogastric junction (EGJ), the possible precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus (BE), and the histologic criteria for mucosal adenocarcinoma.
  • If an area of columnar-lined esophagus (CLE) is only partially involved by intestinal metaplasia, then the latter cannot always be demonstrated in biopsy specimens.
  • Therefore, we do not think that a definition of BE as CLE with histologic intestinal metaplasia is practical.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis. Gastroenterology / standards. Precancerous Conditions / diagnosis. Terminology as Topic
  • [MeSH-minor] Esophagogastric Junction / pathology. Esophagoscopy. Gastroscopy. Humans. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19828957.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 59
  •  go-up   go-down


6. Otabor IA, Abdessalam SF, Erdman SH, Hammond S, Besner GE: Gastric outlet obstruction due to adenocarcinoma in a patient with Ataxia-Telangiectasia syndrome: a case report and review of the literature. World J Surg Oncol; 2009;7:29
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric outlet obstruction due to adenocarcinoma in a patient with Ataxia-Telangiectasia syndrome: a case report and review of the literature.
  • Clinical and radiographic evaluation for malignancy in ataxia-telangiectasia patients is usually atypical, leading to delays in diagnosis.
  • CASE PRESENTATION: We report the case of a 20 year old ataxia-telangiectasia patient with gastric adenocarcinoma that presented as complete gastric outlet obstruction.
  • CONCLUSION: A literature search of adenocarcinoma associated with ataxia-telangiectasia revealed 6 cases.
  • Although there was no correlation between immunoglobulin levels and development of gastric adenocarcinoma, the presence of chronic gastritis and intestinal metaplasia seem to lead to the development of gastric adenocarcinoma.
  • One should consider adenocarcinoma in any patient with ataxia-telangiectasia who presents with non-specific gastrointestinal complaints, since this can lead to earlier diagnosis.
  • [MeSH-major] Adenocarcinoma / complications. Ataxia Telangiectasia / complications. Gastric Outlet Obstruction / etiology. Stomach Neoplasms / complications

  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Ataxia Telangiectasia.
  • MedlinePlus Health Information. consumer health - Ataxia Telangiectasia.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Radiol. 1999 Apr;29(4):225-30 [10199897.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1528-31 [8348486.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Eur J Paediatr Neurol. 2007 Nov;11(6):375-80 [17540590.001]
  • [Cites] Mutat Res. 2008 Feb 1;638(1-2):17-25 [17928013.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Sep;12(9):1033-5 [11007143.001]
  • [Cites] Semin Pediatr Neurol. 2003 Sep;10(3):173-82 [14653405.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Jul;26(7):444-6 [15218420.001]
  • [Cites] JAMA. 1969 Dec 8;210(10):1884-7 [4311128.001]
  • [Cites] Lancet. 1972 Nov 25;2(7787):1112-5 [4117204.001]
  • [Cites] Tohoku J Exp Med. 1977 Feb;121(2):127-31 [191957.001]
  • [Cites] Arch Dis Child. 1979 Sep;54(9):682-6 [92914.001]
  • [Cites] J Natl Cancer Inst. 1986 Jul;77(1):89-92 [3459930.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1987 Summer;9(2):183-4 [3592131.001]
  • [Cites] Q J Med. 1992 Feb;82(298):169-79 [1377828.001]
  • [Cites] J Med Genet. 1979 Apr;16(2):160-1 [458837.001]
  • [Cites] Pediatrics. 1958 Apr;21(4):526-54 [13542097.001]
  • (PMID = 19284625.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC2662841
  •  go-up   go-down


7. Baczewska-Mazurkiewicz D, Rydzewska G, Milewski J, Durlik M, Lao M, Rydzewski A: Magnification chromoendoscopy in comparison to standard chromoendoscopy for detection of intestinal metaplasia in renal transplant recipients. Adv Med Sci; 2006;51:115-8
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnification chromoendoscopy in comparison to standard chromoendoscopy for detection of intestinal metaplasia in renal transplant recipients.
  • Intestinal metaplasia is a feature of atrophic gastritis whereas the diagnosis of Barrett's esophagus is based on histological demonstration of specialized metaplasia.
  • Both conditions are associated with increased risk of adenocarcinoma.
  • The aim of the present study was to assess whether magnification endoscopy improves the diagnostic accuracy of intestinal metaplasia in stomach and in esophagus.
  • MATERIAL AND METHODS: In this non-randomized, feasibility study thirty one (12 women and 19 men) renal transplant recipients, with a mean age of 44.0 years were evaluated for the presence of intestinal metaplasia.
  • The presence of gastritis and intestinal metaplasia was classified according to modified updated Sydney classification.
  • RESULTS: Of 31 patients, 16 patients had endoscopic and histopathological evidence of gastric intestinal metaplasia, and standard endoscopy with methylene blue staining was sufficient for diagnosis (15 from 16).
  • Magnification endoscopy allowed identification of 6 patients with specialized intestinal metaplasia in Barrett's esophagus, which would be otherwise missed.
  • CONCLUSIONS: In this study diagnostic accuracy of standard endoscopy for identification of intestinal metaplasia in the stomach was not improved by the use of magnification endoscopy, but the latter was an accurate method of predicting specialized intestinal metaplasia in Barrett's esophagus.
  • [MeSH-major] Endoscopy, Gastrointestinal / methods. Intestinal Diseases / diagnosis. Intestines / pathology. Kidney Transplantation
  • [MeSH-minor] Adult. Barrett Esophagus / pathology. Feasibility Studies. Female. Humans. Intestinal Neoplasms / diagnosis. Male. Metaplasia / diagnosis. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357289.001).
  • [ISSN] 1896-1126
  • [Journal-full-title] Advances in medical sciences
  • [ISO-abbreviation] Adv Med Sci
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


8. Sánchez-Fayos P, Martín Relloso MJ, González Guirado A, Porres Cubero JC: [Gastric adenocarcinoma: approach to a complex biological reality]. Med Clin (Barc); 2007 Jan 13;128(1):21-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma: approach to a complex biological reality].
  • [Transliterated title] Adenocarcinoma gástrico: intento de aproximación a una realidad biológica compleja.
  • The authors review the complex biological reality of gastric adenocarcinoma from several viewpoints.
  • A good knowledge of this complex biological reality will allow the identification of better markers for an early diagnosis as well as vulnerable etiopathogenetic points for a useful prevention and therapy.
  • [MeSH-major] Adenocarcinoma. Stomach Neoplasms
  • [MeSH-minor] Achlorhydria / complications. Aged. Diet / adverse effects. Early Diagnosis. Epithelial Cells / cytology. Epithelial Cells / pathology. Female. Gastric Mucosa / pathology. Gastritis, Atrophic / complications. Helicobacter Infections / complications. Helicobacter pylori. Humans. Incidence. Male. Metaplasia. Middle Aged. Mitosis. Precancerous Conditions / chemically induced. Precancerous Conditions / pathology. Risk Factors. Stomach / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17266889.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 107
  •  go-up   go-down


9. Bao H, Boussioutas A, Reynolds J, Russell S, Gu M: Imaging of goblet cells as a marker for intestinal metaplasia of the stomach by one-photon and two-photon fluorescence endomicroscopy. J Biomed Opt; 2009 Nov-Dec;14(6):064031
Hazardous Substances Data Bank. D&C Yellow No. 8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of goblet cells as a marker for intestinal metaplasia of the stomach by one-photon and two-photon fluorescence endomicroscopy.
  • Goblet cells are a requirement for the diagnosis of intestinal metaplasia of the stomach.
  • The gastric mucosa is lined by a monolayer of columnar epithelium with some specialization at the crypts, but there are no goblet cells in normal gastric epithelium.
  • The appearance of goblet cells in gastric epithelium is an indicator of potential malignant progression toward adenocarcinoma.
  • Therefore, in vivo three-dimensional imaging of goblet cells is essential for diagnoses of a premalignant stage of gastric cancers called intestinal metaplasia.
  • We used mouse intestine, which has goblet cells, as a model of intestinal metaplasia.
  • These results prove that two-photon fluorescence endomicroscopy is advantageous in diagnoses of a premalignant stage of gastric cancers.
  • [MeSH-minor] Animals. Fluorescein. Imaging, Three-Dimensional / methods. Metaplasia / pathology. Mice. Precancerous Conditions / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUORESCEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20059269.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] TPY09G7XIR / Fluorescein
  •  go-up   go-down


10. Norimura D, Isomoto H, Nakayama T, Hayashi T, Suematsu T, Nakashima Y, Inoue N, Matsushima K, Yamaguchi N, Ohnita K, Mizuta Y, Inoue K, Shikuwa S, Nakao K, Kohno S: Magnifying endoscopic observation with narrow band imaging for specialized intestinal metaplasia in barrett's esophagus with special reference to light blue crests. Dig Endosc; 2010 Apr;22(2):101-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnifying endoscopic observation with narrow band imaging for specialized intestinal metaplasia in barrett's esophagus with special reference to light blue crests.
  • AIM: Barrett's esophagus (BE) with specialized intestinal metaplasia (SIM) is at high risk of esophageal adenocarcinoma.
  • In addition to pit patterns, light blue crests (LBC), blue-whitish patchy areas on the metaplastic epithelia of the stomach, can predict SIM in BE under ME-NBI observation.
  • RESULTS: IM pit pattern with ME-NBI for the diagnosis of IM yielded acceptable sensitivity, specificity and accuracy at 92%, 77% and 83%, respectively.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Endoscopy, Gastrointestinal / methods. Intestinal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Metaplasia. Middle Aged. Predictive Value of Tests. Reproducibility of Results. Retrospective Studies

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447202.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


11. Leys CM, Nomura S, Rudzinski E, Kaminishi M, Montgomery E, Washington MK, Goldenring JR: Expression of Pdx-1 in human gastric metaplasia and gastric adenocarcinoma. Hum Pathol; 2006 Sep;37(9):1162-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Pdx-1 in human gastric metaplasia and gastric adenocarcinoma.
  • Metaplastic lineages represent critical putative preneoplastic precursors for gastrointestinal metaplasia.
  • Two metaplastic processes are associated with gastric cancer: intestinal metaplasia (the presence of intestinal goblet cell containing lineages in the stomach) and spasmolytic polypeptide-expressing metaplasia (SPEM; antralization of the gastric fundus).
  • The transcription factor Pdx-1 is expressed in the adult pancreatic islet cells as well as the gastric antrum and duodenum.
  • We have therefore sought to examine the presence of Pdx-1 expression in gastric metaplasias and gastric adenocarcinoma in humans.
  • Tissue microarrays containing gastric cancers from the fundus and antrum and samples of SPEM and intestinal metaplasia were immunostained for Pdx-1.
  • Although SPEM lineages did not show any staining for Pdx-1, intestinal metaplasia showed strong nuclear staining for Pdx-1.
  • Thus, Pdx-1 expression is not associated with antralizing metaplasia (SPEM) but is associated with intestinal metaplasia.
  • Given the pattern of normal Pdx-1 expression in the duodenum, goblet cell metaplasia in the stomach may reflect the adoption of a duodenal lineage paradigm.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / biosynthesis. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism. Trans-Activators / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Male. Metaplasia

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938521.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P 50 CA95103; United States / NCI NIH HHS / CA / K12 CA090625
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / Trans-Activators; 0 / pancreatic and duodenal homeobox 1 protein
  •  go-up   go-down


12. Elfvin A, Bölin I, Von Bothmer C, Stolte M, Watanabe H, Fändriks L, Vieth M: Helicobacter pylori induces gastritis and intestinal metaplasia but no gastric adenocarcinoma in Mongolian gerbils. Scand J Gastroenterol; 2005 Nov;40(11):1313-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori induces gastritis and intestinal metaplasia but no gastric adenocarcinoma in Mongolian gerbils.
  • OBJECTIVE: The Mongolian gerbil is considered as the model of choice when studying adenocarcinoma related to Helicobacter pylori infection.
  • The stomach was used for culture, and for histology.
  • Intestinal metaplasia was found in both the infected groups.
  • Glands buried in the submucusal layer, changes that might be misinterpreted as adenocarcinoma, were found in 10% of the SS1 and in 65% of the TN2GF4 animals.
  • Adenocarcinoma was not found in any of the gerbils.
  • It is suggested that atypical glands in the muscularis layer are not enough as a diagnostic criterion for gastric adenocarcinoma.
  • It is concluded that adenocarcinoma has not yet been shown convincingly to develop in Mongolian gerbils infected with H. pylori.
  • Nevertheless, it is a model well suited for studying gastritis, gastric ulcer and premalignant changes such as metaplasia.
  • [MeSH-minor] Adenocarcinoma / microbiology. Adenocarcinoma / pathology. Animals. Biopsy, Needle. Disease Models, Animal. Gastric Mucosa / microbiology. Gastric Mucosa / pathology. Gerbillinae. Immunohistochemistry. Intestinal Mucosa / microbiology. Intestinal Mucosa / pathology. Male. Random Allocation. Reference Values. Risk Factors. Sensitivity and Specificity. Stomach Neoplasms / microbiology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334441.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


13. Bîrla R, Iosif C, Gîndea C, Hoară P, Constantinoiu S: [Clinical diagnosis of adenocarcinoma of the esophago-gastric junction]. Chirurgia (Bucur); 2007 Sep-Oct;102(5):511-20
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical diagnosis of adenocarcinoma of the esophago-gastric junction].
  • The aim of the work paper is to present the diagnosis methods of the esophago-gastric junction adenocarcinoma, based on our experience and literature data.
  • The later reveal many novelties about diagnosis means in Barrett's esophagus (BE), the definition and classification of BE, as well as the progress of the endoscopical, immunohistochemical and molecular methods in surveillance of the dysplasia arising in BE and in detection of intraepithelial neoplasia.
  • Early esophago-gastric junction (EGJ) adenocarcinoma (AC) is asymptomatic and its detection may be possible only through endoscopical surveillance.
  • For this reason is necessary to use some more precise methods for identifying intestinal metaplasia on distal esophagus, in patients with gastro-esophageal reflux disease, as well as for risk stratification in patients with dysplasia and for detection of intraepithelial neoplasia.
  • Applying modern methods of immunohistochemical and molecular diagnosis on endoscopical biopsy or esophageal brushing samples, the diagnosis rate for BE, dysplasia and early AC is improved and using the imaging means permits to obtain preoperative TNM staging and tumoral type (Siewert), with implications in therapeutical management.
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis. Esophagogastric Junction. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Barrett Esophagus / complications. Barrett Esophagus / pathology. Diagnosis, Differential. Humans. Neoplasm Staging. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018349.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 47
  •  go-up   go-down


14. Wang DC, Wang LD, Zheng S, Fan ZM, Li JL, Feng CW, Zhang YR, Liu B, Gao SS, He X: [The application of surface-enhanced laser desorption/ionization-time of flight-mass spectrometry in diagnosing dysplasia and chronic atrophic gastric-carditis in population with high risk of gastric-cardia adenocarcinoma]. Zhonghua Nei Ke Za Zhi; 2005 Aug;44(8):573-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The application of surface-enhanced laser desorption/ionization-time of flight-mass spectrometry in diagnosing dysplasia and chronic atrophic gastric-carditis in population with high risk of gastric-cardia adenocarcinoma].
  • OBJECTIVES: To evaluate the serum biomarkers for diagnosis of gastric cardia dysplasia (DYS) and chronic atrophic gastric-carditis (CAG) and to provide a novel screening method for high risk population of gastric-cardia adenocarcinoma (GCA).
  • A set of spectra derived from analysis of serum from 143 symptom-free subjects at high-risk area for GCA, including 63 cases with histologically normal gastric cardia epithelia, 57 of CAG and 23 of DYS, were analyzed by bioinformatics like decision tree classification algorithm.
  • CONCLUSIONS: The gastric cardia lesions of DYS and CAG could be identified by SELDI-TOF-MS technique specifically in symptom-free subjects at high incidence area for GCA.
  • [MeSH-major] Biomarkers, Tumor / blood. Cardia. Gastritis, Atrophic / diagnosis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Chronic Disease. Female. Humans. Male. Mass Screening / methods. Metaplasia / diagnosis. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194406.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, Lauwers GY: Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol; 2009 Jul;22(7):977-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study.
  • The diagnosis of gastric epithelial dysplasia, a precursor lesion of gastric adenocarcinoma, is hindered by interobserver variability and by its resemblance to regenerative changes.
  • Loss of cell polarity, a histological feature of gastric epithelial dysplasia, may be difficult to ascertain, especially in the setting of inflammation or injury.
  • A biomarker of cell polarity could be useful in diagnosis of dysplasia, but has not been reported.
  • Two homologs, lgl1 and lgl2, are present in mammals and lgl2 mRNA is highly expressed in the stomach.
  • The goal of our study was to test the hypothesis that Lgl2 protein expression and/or localization are disrupted in gastric epithelial dysplasia and adenocarcinoma.
  • Routinely processed pathology specimens including 94 benign mucosae of digestive organs, in addition to 36 reactive gastropathy, 57 gastric epithelial dysplasia, and 77 gastric adenocarcinomas, were immunostained for Lgl2 protein.
  • All normal, reactive, and chronically inflamed gastric epithelia showed basolateral Lgl2 staining.
  • Normal esophageal, duodenal, colonic, biliary, and pancreatic duct mucosae, as well as gastric intestinal metaplasia, did not express Lgl2.
  • All but one case each of gastric epithelial dysplasia and adenocarcinoma showed either complete loss of anti-Lgl2 immunoreactivity or diffuse, mostly weak, cytoplasmic staining.
  • Our data suggest that Lgl2 expression is either aberrantly localized or lost in gastric epithelial dysplasia and adenocarcinoma, whereas it is maintained in reactive gastric mucosa.
  • We propose that Lgl2 may be a potential marker to rule out gastric epithelial dysplasia and adenocarcinoma in diagnostic specimens.
  • However, the consistently negative anti-Lgl2 immunoreactivity seen in intestinal metaplasia does not allow differentiation of dysplasia from intestinal metaplasia with reactive change.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins / metabolism. Gastric Mucosa / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


16. Kim CG, Choi IJ, Lee JY, Cho SJ, Nam BH, Kook MC, Hong EK, Kim YW: Biopsy site for detecting Helicobacter pylori infection in patients with gastric cancer. J Gastroenterol Hepatol; 2009 Mar;24(3):469-74
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biopsy site for detecting Helicobacter pylori infection in patients with gastric cancer.
  • BACKGROUND: Helicobacter pylori eradication is recommended in post-gastric cancer resection, but premalignant changes may prevent the detection of H. pylori.
  • The aim of this study was to determine appropriate biopsy site for detecting H. pylori in gastric cancer patients.
  • MATERIALS AND METHODS: Consecutive patients (194) with gastric adenocarcinoma were prospectively enrolled.
  • Sensitivities of histology decreased in correlation with increasing severity of atrophy and intestinal metaplasia (both P < 0.001 using the chi-square test for trend).
  • The proportions of moderate to marked atrophy/intestinal metaplasia at UBGC (12.8%/14.7%) were significantly lower than those at antrum (50.0%/57.8%, P < 0.001 respectively) or UBLC (40.0%/48.9%, P < 0.001 respectively).
  • CONCLUSIONS: The UBGC side is the most sensitive and specific biopsy site to detect H. pylori in gastric cancer patients due to less frequent atrophy and intestinal metaplasia than at the antrum or UBLC side.
  • [MeSH-major] Adenocarcinoma / microbiology. Biopsy / methods. Gastroscopy. Helicobacter Infections / diagnosis. Helicobacter pylori / isolation & purification. Stomach / microbiology. Stomach Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Bacterial / blood. Atrophy. Breath Tests. Female. Humans. Male. Metaplasia. Middle Aged. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Urease / analysis

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19067779.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; EC 3.5.1.5 / Urease
  •  go-up   go-down


17. Ringhofer C, Lenglinger J, Izay B, Kolarik K, Zacherl J, Eisler M, Wrba F, Chandrasoma PT, Cosentini EP, Prager G, Riegler M: Histopathology of the endoscopic esophagogastric junction in patients with gastroesophageal reflux disease. Wien Klin Wochenschr; 2008;120(11-12):350-9
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Discrepancy exists between the endoscopic (rugal folds) and the histopathologic (oxyntic mucosa) definition of proximal stomach.
  • All 19 patients with intestinal metaplasia (18.6%) were identified from 4-quadrant biopsies obtained at the squamocolumnar junction and at 0.5 cm distal from it.
  • Persons with intestinal metaplasia were significantly older, had increased frequency of endoscopic hiatal hernia, higher Hill grade and presence of endoscopic CLE (P < 0.05); no significant difference was observed regarding sex, endoscopic esophagitis or length of endoscopic and histopathologic CLE (P > 0.05).
  • The squamocolumnar junction harbors the highest yield of intestinal metaplasia.
  • [MeSH-major] Endoscopy, Digestive System. Esophagogastric Junction / pathology. Gastroesophageal Reflux / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Barrett Esophagus / diagnosis. Barrett Esophagus / pathology. Biopsy. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / pathology. Female. Gastric Mucosa / pathology. Hernia, Hiatal / diagnosis. Hernia, Hiatal / pathology. Humans. Male. Metaplasia. Middle Aged. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Prospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Wien Klin Wochenschr. 2007;119(13-14):405-11 [17671821.001]
  • [Cites] Am J Gastroenterol. 2007 Jun;102(6):1162-5 [17531009.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):151-9 [16299786.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):11-21 [17592284.001]
  • [Cites] Dis Esophagus. 2000;13(1):5-11 [11005324.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1207-12 [12218577.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1392-9 [17101315.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1611-6 [16863568.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):150-3 [17591489.001]
  • [Cites] Gut. 1997 Nov;41(5):585-9 [9414961.001]
  • [Cites] Gut. 2003 Jun;52(6):791-6 [12740332.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Am J Surg Pathol. 2007 May;31(5):706-10 [17460453.001]
  • [Cites] Arch Pathol Lab Med. 2005 Feb;129(2):164-9 [15679412.001]
  • [Cites] J Gastroenterol. 2006 Jul;41(7):654-61 [16933002.001]
  • [Cites] Am J Gastroenterol. 2004 Feb;99(2):212-7 [15046207.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1416-20 [16863541.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):522-30; discussion 530-2 [9351720.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Am J Gastroenterol. 2005 Aug;100(8):1853-67 [16144130.001]
  • [Cites] Gut. 1993 Jan;34(1):21-7 [8432446.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2007 Sep;4(9):470-1 [17609649.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):960-8 [12826888.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):402-9 [10716154.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):12-7 [16405528.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Scand J Gastroenterol. 1999 Nov;34(11):1065-70 [10582754.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1188-93 [11688579.001]
  • [Cites] Surg Endosc. 1999 Dec;13(12):1184-8 [10594262.001]
  • [Cites] Dis Esophagus. 1998 Apr;11(2):101-5 [9779365.001]
  • [Cites] Gut. 2003 Dec;52(12):1798; author reply 1798-9 [14633968.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2187-93 [17032182.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):190-200 [15654800.001]
  • [Cites] Surg Endosc. 2006 Feb;20(2):235-8 [16391958.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Sep;24 Suppl 2:17-26 [16939429.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):929-36 [12826885.001]
  • [Cites] Dig Dis Sci. 2007 Sep;52(9):2178-82 [17436103.001]
  • [Cites] Am J Gastroenterol. 2002 Feb;97(2):302-11 [11866266.001]
  • [Cites] J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S33-41 [15758657.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):920-4 [15309878.001]
  • [Cites] Gut. 1998 May;42(5):659-62 [9659160.001]
  • [Cites] Scand J Gastroenterol. 2005 Aug;40(8):893-902 [16165707.001]
  • [Cites] Dis Esophagus. 2003;16(1):24-8 [12581250.001]
  • [Cites] Wien Klin Wochenschr. 2007;119(9-10):283-90 [17571232.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):619-26 [11685024.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):40-7 [16360414.001]
  • [Cites] Gut. 2004 Oct;53(10):1402-7 [15361485.001]
  • (PMID = 18709523.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


18. Moretó M: Diagnosis of esophagogastric tumors. Endoscopy; 2005 Jan;37(1):26-32
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of esophagogastric tumors.
  • With regard to gastric tumors, 1) Helicobacter pylori eradication can significantly reduce the development of gastric cancer, but only in patients without precancerous lesions.
  • 2) Intestinal metaplasia types II and III have been shown to have a higher rate of progression to low-grade dysplasia than type I.
  • 4) In patients who have undergone esophagectomy for esophageal cancer, annual follow-up endoscopies are vital for detecting early secondary gastric cancer and ulcerations in which curative treatment is possible.
  • 5) High-resolution endoscopy allows more precise diagnosis of early gastric cancer.
  • The presence of irregular minute vessels and variations in vessel caliber were found to be specific of early gastric cancer.
  • 6) Infrared-ray electronic endoscopy combined with indocyanine green injection appears to be effective in detecting sentinel nodes that contain metastases in patients with gastric cancer.
  • 7) Gastric adenocarcinoma was found to show specific changes in the fluorescence spectra emitted, in comparison with normal gastric mucosa.
  • However, there was wide variation in the emitted autofluorescence spectra in gastric cancer with signet-ring cells in comparison with normal mucosa.
  • [MeSH-major] Endoscopy, Digestive System. Esophageal Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15657854.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


19. Proença-Modena JL, Acrani GO, Brocchi M: Helicobacter pylori: phenotypes, genotypes and virulence genes. Future Microbiol; 2009 Mar;4(2):223-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori is a Gram-negative, microaerophilic bacterium that colonizes the gastric mucus overlying the epithelium of the stomach in more than 50% of the world's population.
  • This gastric colonization induces chronic gastric inflammation in all infected individuals, but only induces clinical diseases in 10-20% of infected individuals.
  • These include peptic ulcers, acute and atrophic gastritis, intestinal metaplasia, gastric adenocarcinoma and gastric B-cell lymphoma.
  • Various bacterial virulence factors are associated with the development of such gastric diseases, and the characterization of these markers could aid medical prognosis, which could be extremely important in predicting clinical outcomes.
  • The purpose of this review is to summarize the role of the phenotypes, virulence-related genes and genotypes of H. pylori in the establishment of gastric colonization and the development of associated diseases.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19257848.001).
  • [ISSN] 1746-0921
  • [Journal-full-title] Future microbiology
  • [ISO-abbreviation] Future Microbiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Virulence Factors
  • [Number-of-references] 176
  •  go-up   go-down


20. Choi SY, Lee JI, Noh TJ, Jang JY, Nam KD, Kim NH, Lee SK, Joo KR, Dong SH, Kim HJ, Kim BH, Chang YW, Chang R: [A case of stump MALT lymphoma after partial gastrectomy]. Korean J Gastroenterol; 2006 May;47(5):394-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrectomy is known to be a risk factor for adenocarcinoma in remnant stomach.
  • It is suggested that reflux of bile juice or duodenal secretion to remnant stomach induces atrophic gastritis, intestinal metaplasia, and gastric adenocarcinoma.
  • Malignant lymphoma in remnant stomach after gastrectomy is very rare.
  • Gastric MALT (mucosa-associated lymphoid tissue) lymphoma is associated with Helicobacter pylori infection but the mechanism of lymphoma development in remnant stomach is still unknown.
  • We report a case of low grade gastric MALT lymphoma of gastric stump after 10 years from partial gastrectomy.
  • [MeSH-major] Gastrectomy. Gastric Stump. Lymphoma, B-Cell, Marginal Zone. Neoplasms, Second Primary. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714883.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


21. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ: Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology; 2008 Apr;134(4):945-52
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands.
  • BACKGROUND & AIMS: A cascade of precursor lesions (eg, atrophic gastritis, intestinal metaplasia, and dysplasia) precedes most gastric adenocarcinomas.
  • Quantification of gastric cancer risk in patients with premalignant gastric lesions is unclear, however.
  • METHODS: To analyze current surveillance practice and gastric cancer risk in patients with premalignant gastric lesions, all patients with a first diagnosis between 1991 and 2004 were identified in the Dutch nationwide histopathology registry (PALGA); follow-up data were evaluated until December 2005.
  • RESULTS: In total, 22,365 (24%) patients were diagnosed with atrophic gastritis, 61,707 (67%) with intestinal metaplasia, 7616 (8%) with mild-to-moderate dysplasia, and 562 (0.6%) with severe dysplasia.
  • Patients with a diagnosis of atrophic gastritis, intestinal metaplasia, or mild-to-moderate dysplasia received re-evaluation in 26%, 28%, and 38% of cases, respectively, compared with 61% after a diagnosis of severe dysplasia (P < .001).
  • The annual incidence of gastric cancer was 0.1% for patients with atrophic gastritis, 0.25% for intestinal metaplasia, 0.6% for mild-to-moderate dysplasia, and 6% for severe dysplasia within 5 years after diagnosis.
  • Risk factors for gastric cancer development were increasing severity of premalignant gastric lesions at initial diagnosis (eg, severe dysplasia, hazard ratio 40.14, 95% confidence interval 32.2-50.1), increased age (eg, 75-84 years, hazard ratio 3.75, 95% confidence interval 2.8-5.1), and male gender (hazard ratio 1.50, 95% CI 1.3-1.7).
  • CONCLUSIONS: Patients with premalignant gastric lesions are at considerable risk of gastric cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Gastric Mucosa / pathology. Gastritis, Atrophic / pathology. Population Surveillance. Precancerous Conditions / epidemiology. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Confidence Intervals. Disease Progression. Endoscopy, Gastrointestinal / methods. Female. Follow-Up Studies. Humans. Incidence. Male. Metaplasia / pathology. Middle Aged. Netherlands / epidemiology. Odds Ratio. Retrospective Studies. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterology. 2009 Apr;136(4):1461-2; author reply 1462 [19245871.001]
  • (PMID = 18395075.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Hoshihara Y, Kogure T, Yamamoto T, Hashimoto M, Hoteya O: [Endoscopic diagnosis of Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1394-8
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic diagnosis of Barrett's esophagus].
  • The prevalence of Barrett's esophagus and Barrett's adenocarcinoma is very low.
  • But in Western countries Barrett's mucosa is defined as CLE with intestinal metaplasia, and many cases of Barrett's esophagus and Barrett's adenocarcinoma are reported.
  • The definite endoscopic diagnosis of Barrett's mucosa cannot be so easy.
  • In no cases were the longitudinal vessels observed under the gastric mucosa beyond the esophageal hiatus.
  • It is peculiar to the esophagus to be able to observe subepithelial longitudinal vessels in the vicinity of the esophago-gastric junction.
  • When longitudinal vessels are found only under the columnar epithelium at the oral side over the esophageal hiatus from the stomach, this indicates Barrett's epithelium.
  • Thus the definite diagnosis of Barrett's epithelium can be made by endoscopy.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / pathology. Endoscopy, Gastrointestinal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101228.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


23. Park SY, Jeon SW, Jung MK, Cho CM, Tak WY, Kweon YO, Kim SK, Choi YH: Long-term follow-up study of gastric intraepithelial neoplasias: progression from low-grade dysplasia to invasive carcinoma. Eur J Gastroenterol Hepatol; 2008 Oct;20(10):966-70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up study of gastric intraepithelial neoplasias: progression from low-grade dysplasia to invasive carcinoma.
  • BACKGROUND AND STUDY AIMS: A gastric intraepithelial neoplasia (IEN) is usually regarded as a precancerous lesion; however, the natural history of the gastric IEN has not been clarified.
  • We aimed to evaluate the progression of dysplasia in gastric IENs.
  • PATIENTS AND METHODS: As a retrospective study, we reviewed 26 gastric adenomas with low-grade dysplasia (LGD) and one with high-grade dysplasia (HGD) from 18 patients.
  • The histological diagnosis was classified according to the Vienna classification.
  • We reviewed clinical (age and sex), morphological (size, color, shape, location in stomach, surface nodularity, and presence of the erosion), and histological (histological diagnosis, infection with Helicobacter pylori, infiltration of inflammatory cells, atrophy, intestinal metaplasia, microscopic erosions, and glandular appearance) characteristics with regard to progression of dysplasia.
  • One IEN with HGD and three IENs with LGD progressed to invasive adenocarcinoma (category 5).
  • Four gastric IENs with LGD progressed to HGD (category 4).
  • CONCLUSION: For the potential risk of progressive dysplasia, gastric IENs should be treated actively using the recently advanced therapeutic endoscopic techniques, regardless of the degrees of dysplasia.
  • [MeSH-major] Gastric Mucosa / pathology. Precancerous Conditions / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Chi-Square Distribution. Disease Progression. Female. Follow-Up Studies. Gastroscopy. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Male. Metaplasia / pathology. Middle Aged. Neoplasm Staging. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18787462.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Pereira C, Sousa H, Ferreira P, Fragoso M, Moreira-Dias L, Lopes C, Medeiros R, Dinis-Ribeiro M: -765G &gt; C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol; 2006 Sep 14;12(34):5473-8
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] -765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia.
  • AIM: To investigate the relationship between the -765G > C COX-2 polymorphism and the development of different gastric lesions: atrophy or intestinal metaplasia and gastric adenocarcinoma.
  • METHODS: A cross-sectional study was performed involving 320 Portuguese individuals (210 without evidence of neoplastic disease, 73 patients with gastric adenocarcinomas and 37 with atrophy or intestinal metaplasia) using a PCR-RFLP method.
  • RESULTS: -765C allele was overrepresented in the patients with gastric adenocarcinoma (51%) when compared either with the control group (38%) or patients with atrophy or intestinal metaplasia (27%).
  • Callele was found to be very common in our population (0.22), and a multivariate logistic regression analysis revealed nearly 3-fold increased risk for the progression to gastric adenocarcinoma in patients with atrophy or intestinal metaplasia carrying the -765C allele (OR = 2.67, 95% CI = 1.03-6.93; P = 0.04).
  • CONCLUSION: -765C carrier status should be considered as another susceptibility marker for gastric adenocarcinoma development in patients with atrophy or intestinal metaplasia.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Cyclooxygenase 2 / genetics. Intestines / pathology. Membrane Proteins / genetics. Polymorphism, Genetic / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Alleles. Atrophy / genetics. Atrophy / pathology. Cross-Sectional Studies. Cystine / analysis. DNA, Neoplasm / analysis. Female. Genetic Predisposition to Disease. Guanine / analysis. Humans. Male. Metaplasia / genetics. Metaplasia / pathology. Middle Aged. Portugal. Regression Analysis. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2005 Jul 1;160(1):49-54 [15949570.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4090-6 [15930344.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):565-76 [16083713.001]
  • [Cites] World J Gastroenterol. 2005 Aug 21;11(31):4908-11 [16097070.001]
  • [Cites] World J Gastroenterol. 2005 Aug 21;11(31):4918-22 [16097073.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):354-62 [16489633.001]
  • [Cites] Eur J Cancer Prev. 2003 Jun;12(3):205-11 [12771559.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(17):2507-20 [14602137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):415-6 [14707264.001]
  • [Cites] J Clin Pathol. 2004 Feb;57(2):177-82 [14747445.001]
  • [Cites] Prostate. 2004 May 15;59(3):268-74 [15042602.001]
  • [Cites] JAMA. 2004 May 12;291(18):2221-8 [15138244.001]
  • [Cites] Carcinogenesis. 2004 Jun;25(6):961-6 [14754878.001]
  • [Cites] Eur J Cancer Prev. 2004 Jun;13(3):177-81 [15167216.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1760-4 [15150618.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4266s-4269s [15217972.001]
  • [Cites] J Allergy Clin Immunol. 2004 Aug;114(2):248-53 [15316498.001]
  • [Cites] World J Gastroenterol. 2004 Oct 1;10(19):2809-13 [15334675.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(8):2180-4 [2951737.001]
  • [Cites] Trends Genet. 1989 Dec;5(12):391 [2623762.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):991-4 [10070952.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Nov;155(1):42-6 [15527901.001]
  • [Cites] Clin Exp Allergy. 2004 Nov;34(11):1714-8 [15544595.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2467-72 [15308583.001]
  • [Cites] Cancer Lett. 2005 Jan 10;217(1):11-6 [15596291.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):449-57 [15550453.001]
  • [Cites] Stroke. 2005 Feb;36(2):276-80 [15604423.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):760-4 [15721423.001]
  • [Cites] World J Gastroenterol. 2005 Feb 28;11(8):1228-31 [15754411.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):616-9 [15767339.001]
  • [Cites] Prostate. 2000 Jan;42(1):73-8 [10579801.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):135-8 [10656441.001]
  • [Cites] J Clin Invest. 2000 May;105(10):1473-82 [10811855.001]
  • [Cites] Curr Med Chem. 2000 Nov;7(11):1163-70 [11032965.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):333-8 [11180079.001]
  • [Cites] Endocr Relat Cancer. 2001 Jun;8(2):97-114 [11397667.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Jul;127(7):411-7 [11469677.001]
  • [Cites] Br J Pharmacol. 2001 Nov;134(6):1137-50 [11704632.001]
  • [Cites] Pathology. 2001 Nov;33(4):469-74 [11827414.001]
  • [Cites] J Cell Physiol. 2002 Mar;190(3):279-86 [11857443.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):1129-41 [11891209.001]
  • [Cites] J Hum Genet. 2002;47(8):413-8 [12181642.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):801-7 [12209724.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1631-6 [12377741.001]
  • [Cites] J Thromb Thrombolysis. 2002 Aug;14(1):51-8 [12652150.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):674-7 [12679908.001]
  • [Cites] Eur J Cancer. 2003 May;39(8):1041-52 [12736102.001]
  • [Cites] Lung Cancer. 2005 Apr;48(1):11-7 [15777967.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3633-42 [15867358.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1445-61 [15887126.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 26;334(2):588-92 [16009345.001]
  • (PMID = 17006983.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Membrane Proteins; 48TCX9A1VT / Cystine; 5Z93L87A1R / Guanine; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  • [Other-IDs] NLM/ PMC4088228
  •  go-up   go-down


25. Chandrasoma P: Controversies of the cardiac mucosa and Barrett's oesophagus. Histopathology; 2005 Apr;46(4):361-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Confusion regarding the diagnosis of Barrett's oesophagus exists because of a false dogma that cardiac mucosa is normally present in the gastro-oesophageal junctional region.
  • Recent data indicate that the only normal epithelia in the oesophagus and proximal stomach are squamous epithelium and gastric oxyntic mucosa.
  • When this fact is recognized, it becomes easy to develop precise histological definitions for the normal state (presence of only squamous and oxyntic mucosa), metaplastic oesophageal columnar epithelium (cardiac mucosa with and without intestinal metaplasia, and oxynto-cardiac mucosa), the gastro-oesophageal junction (the proximal limit of gastric oxyntic mucosa), the oesophagus (that part of the foregut lined by squamous and metaplastic columnar epithelium), reflux disease (the presence of metaplastic columnar epithelium), and Barrett's oesophagus (cardiac mucosa with intestinal metaplasia).
  • It is also possible to assess accurately the severity of reflux which is directly proportional to the amount of metaplastic columnar epithelium, and the risk of adenocarcinoma which is related to the amount of dysplasia in intestinal metaplastic epithelium present within the columnar lined segment of the oesophagus.
  • Histopathological precision cannot be matched by any other modality and can convert the confusion that exists regarding diagnosis of Barrett's oesophagus to complete lucidity in a manner that is simple, accurate, and reproducible.
  • [MeSH-major] Barrett Esophagus / pathology. Cardia / pathology. Gastric Mucosa / pathology
  • [MeSH-minor] Esophagogastric Junction / pathology. Humans. Metaplasia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2006 Jul;49(1):97-8; author reply 98 [16842257.001]
  • (PMID = 15810947.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 48
  •  go-up   go-down


26. Weimann A, Zimmermann M, Gross M, Slevogt H, Rieger A, Morawietz L: CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma. Int J Surg Pathol; 2010 Oct;18(5):330-7
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
  • BACKGROUND: Barrett's mucosa is a risk factor for esophageal adenocarcinoma and should be detected at an early stage.
  • Aberrant CDX2 expression has been demonstrated in Barrett's metaplasia, esophagitis, and intestinal metaplasia of the stomach.
  • METHODS: The relationship between CDX2 and LI-cadherin expression was investigated in normal gastroesophageal (n = 24) and in Barrett's (n = 20) mucosa, in low-grade (n = 15) and high-grade (n = 13) intraepithelial neoplasia (IEN) as well as in esophageal adenocarcinoma (n = 16), using immunohistochemistry.
  • In adenocarcinoma, the expression of LI-cadherin and CDX2 was significantly weaker or absent.
  • CONCLUSIONS: CDX2 and LI-cadherin are sensitive markers of intestinal metaplasia with or without dysplasia in the upper gastrointestinal tract.
  • Both can be helpful for the early histologic diagnosis of Barrett's esophagus and its subsequent lesions; however, they do not significantly discern between different grades of dysplasia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Biomarkers / metabolism. Cadherins / metabolism. Homeodomain Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20444732.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CDH17 protein, human; 0 / CDX2 protein, human; 0 / Cadherins; 0 / Homeodomain Proteins
  •  go-up   go-down


27. Farnedi A, Eusebi LH, Poli F, Foschini MP: Immunohistochemical expression of the human sodium/iodide symporter distinguishes malignant from benign gastric lesions. Int J Surg Pathol; 2009 Aug;17(4):327-34
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of the human sodium/iodide symporter distinguishes malignant from benign gastric lesions.
  • The aim was to evaluate the immunohistochemical expression of the human homolog of NIS (hNIS) in a wide spectrum of gastric lesions.
  • MATERIALS AND METHODS: Seventy-seven samples were stained immunohistochemically with a monoclonal antibody for hNIS, including 14 with normal gastric mucosa, 14 with chronic atrophic gastritis with foveolar hyperplasia, 15 with chronic atrophic gastritis with intestinal metaplasia, 6 with chronic atrophic gastritis with atypical regenerative hyperplasia, 8 with chronic atrophic gastritis with dysplasia, 15 with invasive adenocarcinoma, 3 with well-differentiated neuroendocrine tumor, and 2 with gastrointestinal stromal tumors (GISTs).
  • RESULTS: hNIS stained the basolateral cytoplasmic portion of foveolae in normal mucosa, in 13 cases of chronic atrophic gastritis with foveolar hyperplasia, and in only 1 case of regenerative atypical hyperplasia. hNIS was consistently absent in intestinal metaplasia, in dysplastic glands, and in the cells constituting invasive carcinoma, well-differentiated neuroendocrine tumors, and GIST.
  • [MeSH-major] Gastritis, Atrophic / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Neuroendocrine Tumors / diagnosis. Precancerous Conditions / pathology. Stomach Neoplasms / diagnosis. Symporters / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Chronic Disease. Diagnosis, Differential. Female. Gastric Mucosa / metabolism. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Male. Metaplasia / diagnosis. Metaplasia / metabolism. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19124451.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Symporters; 0 / sodium-iodide symporter
  •  go-up   go-down


28. Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, Montgomery E, Goldenring JR: Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery; 2007 Jan;141(1):41-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer.
  • PURPOSE: Prothymosin-alpha and ERp57 were previously identified as markers for gastric metaplasia in a mouse model of Helicobacter-induced gastric metaplasia and neoplasia.
  • In this paper we assess whether the expression of these putative biomarkers in humans is correlated with gastric metaplasia and adenocarcinoma and clinical outcomes.
  • METHODS: Eight tissue microarrays, containing 749 paraffin-embedded tissue cores from 164 gastric cancer patients, were stained for prothymosin-alpha and ERp57 by horseradish peroxidase immunohistochemical techniques.
  • RESULTS: Prothymosin-alpha stained a significantly higher percentage of nuclei in cancer and metastases compared with normal gastric mucosa.
  • ERp57 staining was significantly decreased in cancer and metastases compared with both normal gastric mucosa and metaplasias.
  • CONCLUSIONS: These results suggest that although prothymosin-alpha is overexpressed in gastric adenocarcinoma, it is not associated with alterations in survival.
  • In contrast, loss of ERp57 expression correlated with more aggressive disease and could provide useful prognostic information for gastric cancer patients.
  • [MeSH-major] Protein Disulfide-Isomerases / metabolism. Protein Precursors / metabolism. Stomach Neoplasms / metabolism. Thymosin / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Down-Regulation. Endoplasmic Reticulum / metabolism. Humans. Immunohistochemistry. Metaplasia / metabolism. Molecular Chaperones / metabolism. Prognosis. Protein Array Analysis. Retrospective Studies. Stomach / metabolism. Stomach / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17188166.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA95103; United States / NCI NIH HHS / CA / CA67108; United States / NCI NIH HHS / CA / K12 CA090625; United States / NCI NIH HHS / CA / P50 CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Molecular Chaperones; 0 / Protein Precursors; 0 / prothymosin alpha; 61512-21-8 / Thymosin; EC 5.3.4.1 / Protein Disulfide-Isomerases; EC 5.3.4.1. / PDIA3 protein, human
  •  go-up   go-down


29. Tan YK, Fielding JW: Early diagnosis of early gastric cancer. Eur J Gastroenterol Hepatol; 2006 Aug;18(8):821-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early diagnosis of early gastric cancer.
  • The prognosis of gastric cancer is closely related to the stage of disease at diagnosis.
  • Early gastric cancer, whereby disease is limited to mucosa and submucosa, confers a survival rate of greater than 90% in 5 years in many centres.
  • Gastric cancer is still a major cause of cancer mortality worldwide.
  • Hence, strategy has been directed to screen symptomatic individuals who are at higher risk of gastric cancer.
  • Most patients with early gastric cancer present with symptoms indistinguishable from benign peptic ulcer disease.
  • Screening for this group of patients improves detection rate of early gastric cancer and therefore its prognosis.
  • There is compelling evidence for the role of H. pylori in the initiation of Correa's cascade (stepwise progression from chronic active gastritis, atrophic gastritis, intestinal metaplasia, dysplasia and finally adenocarcinoma).
  • However, it is not known whether this might effectively prevent gastric cancer in either low or high-risk population.
  • [MeSH-major] Stomach Neoplasms / diagnosis
  • [MeSH-minor] Early Diagnosis. Endoscopy. Humans. Incidence. Mass Screening. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825897.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 132
  •  go-up   go-down


30. Fukasawa T, Suzuki S, Fujii H: [A case report of early gastric cancer with Paneth-like tumor cells]. Nihon Shokakibyo Gakkai Zasshi; 2006 Nov;103(11):1251-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of early gastric cancer with Paneth-like tumor cells].
  • A 55-year-old man was given a diagnosis of grade 0IIc type gastric cancer of the midgastric posterior wall following endoscopy of the upper digestive tract, and subsequently underwent distal gastrectomy.
  • Tumor cells resembling Paneth cells were occasionally observed in differentiated adenocarcinoma that had invaded the submucosal layer, the tumor was CD10-positive, and showed differentiation to complete intestinal metaplasia.
  • Although complete intestinal metaplasia is associated with a low incidence of malignant transformation, this case was considered to be different from complete intestinal metaplasia, on which a mutation of the gene of p53 is involved in the early period of carcinogenesis.
  • [MeSH-major] Adenocarcinoma / pathology. Paneth Cells / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085906.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Chandrasoma P, Wijetunge S, Demeester SR, Hagen J, Demeester TR: The histologic squamo-oxyntic gap: an accurate and reproducible diagnostic marker of gastroesophageal reflux disease. Am J Surg Pathol; 2010 Nov;34(11):1574-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsies were obtained from the esophagus, around the gastroesophageal junction and the stomach: proximal, body, and antrum.
  • Patients who had oxyntocardiac±cardiac±intestinal epithelia between the squamous epithelium proximally and the proximal limit of gastric oxyntic mucosa distally were defined as having a squamo-oxyntic gap.
  • Only oxyntocardiac epithelium was seen in 190 (11.5%) of the patients, oxyntocardiac and cardiac epithelia in 898 (54.3%), and intestinal metaplasia in addition to the other 2 epithelial types in 567 (34.2%).
  • The prevalence of intestinal metaplasia was directly proportional to length of the squamo-oxyntic gap, being 24.3% (340/1399) when the length was <1 cm, and 83.5% (147/176) with length 1 to 5 cm.
  • All patients with a length more than 5 cm had intestinal metaplasia.
  • The distribution of the 3 epithelia was constant irrespective of the length of the squamocolumnar gap; intestinal metaplasia, when present, was seen maximally in the proximal region of the gap, cardiac epithelium intermediate and oxyntocardiac epithelium in the most distal segment of the gap.
  • Distal gastric biopsies showed no evidence of significant inflammation, intestinal metaplasia or Helicobacter pylori infection in 1543 (93.2%) of the patients, indicating that the squamo-oxyntic gap was largely independent of gastric pathology.
  • The distal limit of the squamo-oxyntic gap, which is the junction between oxyntocardiac and gastric oxyntic epithelium is the true gastroesophageal junction.
  • The presence of intestinal metaplasia within the squamo-oxyntic gap is the most accurate risk indicator for esophageal adenocarcinoma and defines Barrett esophagus.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Epithelial Cells / pathology. Esophageal Neoplasms / diagnosis. Esophagus / pathology. Gastroesophageal Reflux / diagnosis. Parietal Cells, Gastric / pathology. Precancerous Conditions / diagnosis
  • [MeSH-minor] Biopsy. California. Endoscopy, Gastrointestinal. Humans. Metaplasia. Predictive Value of Tests. Reproducibility of Results. Retrospective Studies. Risk Assessment. Risk Factors. Severity of Illness Index

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 May;35(5):773; author reply 773-4 [21502913.001]
  • (PMID = 20871393.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Goto Y, Ando T, Nishio K, Kawai S, Ishida Y, Naito M, Goto H, Hamajima N: Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy. Int J Med Sci; 2007;4(1):1-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy.
  • BACKGROUND: Various single nucleotide polymorphisms (SNPs) have explained the association between Helicobacter pylori (H. pylori) and gastric atrophy and cancer.
  • This study investigated the associations of Grb2 associated binder 1 (Gab1) polymorphism and the combination of PTPN11 gene encoding src homology 2 domain-containing protein tyrosine phosphatase-2 (SHP2) and Gab1 gene with gastric cancer and gastric atrophy among H. pylori seropositive subjects.
  • METHODS: A single nucleotide polymorphism at intron 2 of Gab1 (JST164345) was examined for 454 Japanese health checkup examinees (126 males and 328 females) aged 35 to 85 without a history of gastric cancer and 202 gastric cancer patients (134 males and 68 females) aged 33 to 94 with pathologically confirmed diagnosis of gastric adenocarcinoma.
  • Among seropositive healthy controls, the OR of the Gab1 G/A+A/A for gastric atrophy was significant (OR=1.95, 95% CI: 1.12 -3.40).
  • Seropositive individuals with PTPN11 G/G and Gab1 G/A+A/A demonstrated the highest risk of gastric atrophy with significance (OR=3.49, 95% CI: 1.54-7.90) relative to PTPN11 G/A+A/A and Gab1 G/G, the lowest risk combination, as a reference.
  • Compared to gastric cancer case, the Gab1 did not influence the step of atrophy/metaplasia-gastric cancer sequence.
  • CONCLUSIONS: This study represents that the Gab1 polymorphism was associated with the low risk of H. pylori infection and the high risk of gastric atrophy among seropositive healthy controls, and that seropositive individuals with PTPN11 G/G and Gab1 G/A+G/G were associated with the greatest risk of gastric atrophy.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Gastric Mucosa / pathology. Helicobacter Infections / etiology. Helicobacter pylori. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Atrophy. Female. Humans. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Male. Metaplasia. Middle Aged. Odds Ratio. Protein Phosphatase 2. Protein Tyrosine Phosphatase, Non-Receptor Type 11. Protein Tyrosine Phosphatases / genetics. Protein Tyrosine Phosphatases / metabolism. Risk Factors. SH2 Domain-Containing Protein Tyrosine Phosphatases. Stomach Neoplasms / etiology. src Homology Domains

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2000 Apr;37(3-4):299-307 [10752981.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13842-8 [10788507.001]
  • [Cites] Science. 2002 Jan 25;295(5555):683-6 [11743164.001]
  • [Cites] J Clin Pathol. 2001 Sep;54(9):703-6 [11533078.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] J Biol Chem. 2001 Jun 29;276(26):24380-7 [11323411.001]
  • [Cites] Jpn J Cancer Res. 2001 Apr;92(4):383-9 [11346459.001]
  • [Cites] Jpn J Cancer Res. 2000 Sep;91(9):865-8 [11011111.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(22):8513-25 [11046147.001]
  • [Cites] J Cell Biol. 2000 Jun 26;149(7):1419-32 [10871282.001]
  • [Cites] Helicobacter. 2001 Dec;6(4):294-9 [11843961.001]
  • [Cites] FEBS Lett. 2002 Mar 27;515(1-3):1-7 [11943184.001]
  • [Cites] Int J Mol Med. 2002 Sep;10(3):321-6 [12165808.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1546-56 [12629518.001]
  • [Cites] Microbes Infect. 2003 Feb;5(2):143-50 [12650772.001]
  • [Cites] Mol Biol Cell. 2003 Apr;14(4):1691-708 [12686619.001]
  • [Cites] Gastric Cancer. 2003;6(4):230-6 [14716517.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2007-15 [15026337.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17205-16 [14963045.001]
  • [Cites] Lancet. 1975 Jul 12;2(7924):58-60 [49653.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):203-8 [16032704.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1809-16 [10068651.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16643-6 [9642214.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1189-202 [8622663.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] Science. 1993 Mar 12;259(5101):1611-4 [7681217.001]
  • [Cites] Science. 1993 Mar 12;259(5101):1607-11 [8096088.001]
  • (PMID = 17211494.001).
  • [ISSN] 1449-1907
  • [Journal-full-title] International journal of medical sciences
  • [ISO-abbreviation] Int J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GAB1 protein, human; 0 / Intracellular Signaling Peptides and Proteins; EC 3.1.3.16 / Protein Phosphatase 2; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / SH2 Domain-Containing Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC1752235
  •  go-up   go-down


33. Li JH, Shi XZ, Lv S, Liu M, Xu GW: Effect of Helicobacter pylori infection on p53 expression of gastric mucosa and adenocarcinoma with microsatellite instability. World J Gastroenterol; 2005 Jul 28;11(28):4363-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Helicobacter pylori infection on p53 expression of gastric mucosa and adenocarcinoma with microsatellite instability.
  • AIM: To investigate the relationship between Helicobacter pylori (H pylori) infection, microsatellite instability and the expressions of the p53 in gastritis, intestinal metaplasia and gastric adenocarcinoma and to elucidate the mechanism of gastric carcinogenesis relating to H pylori infection.
  • METHODS: One hundred and eight endoscopic biopsies and gastric adenocarcinoma were available for the study including 33 cases of normal, 45 cases of gastritis, 30 cases of intestinal metaplasia, and 46 cases of gastric adenocarcinoma.
  • MSI was defined as the peak shift in the DNA of the gastric tissue compared with that of the peripheral blood samples.
  • RESULTS: H pylori infection was detected in the samples of gastritis, intestinal metaplasia, and gastric adenocarcinoma and the infection frequencies were 84.4%, 76.7%, and 65.2%, respectively, whereas no H pylori infection was detected in the samples of normal control.
  • No MSI was detected in gastritis samples, one MSI-H and two MSI-L were detected among the 30 intestinal metaplasia samples, and 12 MSI-H and 3 MSI-L were detected in the 46 gastric carcinomas.
  • In those gastric carcinomas, the MSI-H frequency in H pylori-positive group was significantly higher than that in H pylori-negative group.
  • P53-positive immunohistochemical staining was detected in 13.3% of intestinal metaplasia samples and in 43.5% of gastric carcinoma samples.
  • CONCLUSION: H pylori affect the p53 pattern in gastric mucosa when MMR system fails to work.
  • Mutations of the p53 gene seem to be an early event in gastric carcinogenesis.
  • [MeSH-major] Adenocarcinoma / genetics. Helicobacter Infections / physiopathology. Helicobacter pylori. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Female. Gastric Mucosa / microbiology. Gastric Mucosa / physiology. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Repeats. Middle Aged

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038035.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC4434663
  •  go-up   go-down


34. Ndububa DA, Agbakwuru EA, Olasode BJ, Aladegbaiye AO, Adekanle O, Arigbabu AO: Correlation between endoscopic suspicion of gastric cancer and histology in Nigerian patients with dyspepsia. Trop Gastroenterol; 2007 Apr-Jun;28(2):69-71
Genetic Alliance. consumer health - Dyspepsia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between endoscopic suspicion of gastric cancer and histology in Nigerian patients with dyspepsia.
  • Gastric mucosal biopsies of 77 dyspeptic patients whose endoscopic features were suggestive of cancer and 56 patients with uncomplicated duodenal ulcer (DU) were subjected to histopathological analysis.
  • Gastric cancer was confirmed in 18 (23.4%) of the 77 patients but not in 59 (76.6%).
  • 4 (5.2%) of the 18 patients had early gastric cancer (EGC).
  • Histopathological findings in the stomach biopsy of the 59 patients in whom cancer could not be confirmed were compared with those of the 56 patients with DU.
  • Intestinal metaplasia (IM) was present in 32.2% of the 59 cases with endoscopic suspicion of gastric cancer and in 16.1% of the 56 DU controls (P < 0.05).
  • The difference in the prevalence of gastric mucosal atrophy and Helicobacter pylori infection between the two groups (83% vs. 71.4%) did not reach statistical significance (P > 0.10).
  • All 18 patients with gastric cancer were positive for Helicobacter pylori and the prevalence of the infection approached 95% in those with IM and MALT.
  • This study shows that IM and MALT present with endoscopic appearances that resemble that of gastric cancer and that along with the latter, their main aetiological agent is Helicobacter pylori.
  • [MeSH-major] Gastric Mucosa / pathology. Gastroscopy. Lymphoma, B-Cell, Marginal Zone / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Case-Control Studies. Dyspepsia / etiology. Female. Helicobacter Infections / epidemiology. Helicobacter pylori / isolation & purification. Humans. Male. Middle Aged. Nigeria. Prospective Studies. Stomach Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050843.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


35. Albayrak F, Uyanik MH, Dursun H, Albayrak Y, Altas S, Uyanik A, Cerrah S, Bayir Y: Should increased levels of urinary 8-hydroxydeoxyguanosine in chronic gastritis imply intestinal metaplasia or gastric atrophy? South Med J; 2010 Aug;103(8):753-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should increased levels of urinary 8-hydroxydeoxyguanosine in chronic gastritis imply intestinal metaplasia or gastric atrophy?
  • OBJECTIVES: Helicobacter pylori (H pylori) infection induces chronic inflammation that can progress to gastric atrophy, intestinal metaplasia, and gastric adenocarcinoma.
  • We have examined oxidative damage caused by Helicobacter pylori, metaplasia, and atrophy of gastric mucosal cells in patients with chronic gastritis by measuring their urinary 8-hydroxydeoxyguanosine (8-OHdG) levels.
  • The level of urinary 8-OHdG was markedly higher in patients with gastric atrophy and intestinal metaplasia than in those without (P=0.000, P=0.002, respectively).
  • There were significant correlations between levels of urinary 8-OHdG and both the atrophy score (r=0.441, P=0.000) and the intestinal metaplasia score (r=0.436, P=0.000).
  • In patients with high levels of urinary 8-OHdG, endoscopic procedures or even pathological investigation may then be carried out, with the consideration that there is a high risk of intestinal metaplasia or atrophy.
  • [MeSH-major] Deoxyguanosine / analogs & derivatives. Gastric Mucosa / pathology. Gastritis / urine. Intestinal Mucosa / pathology
  • [MeSH-minor] Atrophy / etiology. Atrophy / urine. Chronic Disease. Female. Helicobacter Infections / complications. Helicobacter Infections / urine. Helicobacter pylori. Humans. Male. Metaplasia / etiology. Metaplasia / urine. Middle Aged. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622725.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


36. Broder IA, Moroshek AA, Sigal EI, Burmistrov MV: [An integrated approach to diagnosis and treatment of Barrett's esophagus]. Eksp Klin Gastroenterol; 2009;(4):48-51
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An integrated approach to diagnosis and treatment of Barrett's esophagus].
  • Barrett's oesophagus is a condition when the oesophagus adenocarcinoma risk increases.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Biopsy. Combined Modality Therapy. Esophagoscopy. Esophagus / pathology. Esophagus / surgery. Female. Fundoplication. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / epidemiology. Gastroesophageal Reflux / pathology. Humans. Intestines / pathology. Laparoscopy. Laser Coagulation. Male. Metaplasia / epidemiology. Metaplasia / pathology. Middle Aged. Stomach / pathology. Treatment Outcome. Vagotomy, Proximal Gastric. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19960995.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


37. Miao XP, Li JS, Li HY, Zeng SP, Zhao Y, Zeng JZ: Expression of ornithine decarboxylase in precancerous and cancerous gastric lesions. World J Gastroenterol; 2007 May 28;13(20):2867-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ornithine decarboxylase in precancerous and cancerous gastric lesions.
  • AIM: To investigate the expression of ornithine decarboxylase (ODC) in precancerous and cancerous gastric lesions.
  • METHODS: We studied the expression of ODC in gastric mucosa from patients with chronic superficial gastritis (CSG, n=32), chronic atrophic gastritis [CAG, n=43; 15 with and 28 without intestinal metaplasia (IM)], gastric dysplasia (DYS, n=11) and gastric cancer (GC, n=48) tissues using immunohistochemical staining.
  • All 134 biopsy specimens of gastric mucosa were collected by gastroscopy.
  • CONCLUSION: The expression of ODC is positively correlated with the degree of malignity of gastric mucosa and development of gastric lesions.
  • This finding indicates that ODC may be used as a good biomarker in the screening and diagnosis of precancerous lesions.
  • [MeSH-major] Adenocarcinoma / enzymology. Ornithine Decarboxylase / metabolism. Precancerous Conditions / enzymology. Stomach Neoplasms / enzymology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Gastric Mucosa / enzymology. Gastric Mucosa / pathology. Gastritis / enzymology. Gastritis / pathology. Gastritis, Atrophic / enzymology. Gastritis, Atrophic / pathology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Metaplasia / enzymology. Metaplasia / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17569126.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 4.1.1.17 / Ornithine Decarboxylase
  • [Other-IDs] NLM/ PMC4395642
  •  go-up   go-down


38. Roessler K, Mönig SP, Schneider PM, Hanisch FG, Landsberg S, Thiele J, Hölscher AH, Dienes HP, Baldus SE: Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis. World J Gastroenterol; 2005 Jun 7;11(21):3182-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis.
  • CDX2 represents a transcription factor for various intestinal genes (including MUC2) and thus an important regulator of intestinal differentiation, which could previously be identified in gastric carcinomas and intestinal metaplasia.
  • METHODS: Formalin-fixed and paraffin-embedded tissues from 190 gastric carcinoma patients were stained with monoclonal antibodies recognizing CDX2 and MUC2, respectively.
  • Both antigens were present in >80% of areas exhibiting intestinal metaplasia.
  • CONCLUSION: CDX2 and MUC2 play an important role in the differentiation of normal, inflamed, and neoplastic gastric tissues.
  • According to our results, loss of CDX2 may represent a marker of tumor progression in early gastric cancer and carcinomas with an intestinal phenotype.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / metabolism. Mucins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Early Diagnosis. Female. Humans. Male. Middle Aged. Mucin-2. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929165.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  • [Other-IDs] NLM/ PMC4316046
  •  go-up   go-down


39. He XX, Yang J, Ding YW, Liu W, Shen QY, Xia HH: Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut; 2006 Jun;55(6):797-802
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis.
  • This study was conducted to determine whether MIF expression is associated with gastric pathology and whether MIF expression is increased in malignant gastric cells in vitro.
  • MATERIALS AND METHODS: Patients with a normal gastric mucosa, Helicobacter pylori infected gastritis, intestinal metaplasia, and gastric adenocarcinoma were included.
  • Immunohistochemistry and enzyme linked immunosorbent assay (ELISA) were used to determine MIF expression in gastric epithelial cells and MIF levels in serum, respectively.
  • Five gastric cancer cell lines (AGS, MKN-45, MKN-28, MGC-803, and SGC-7901) and one non-malignant gastric cell line (GES-1) were cultured for 24 hours.
  • RESULTS: The percentage of MIF expressing epithelial cells was low in normal mucosa (12%) but substantially higher in gastritis (52%), intestinal metaplasia (66%), and gastric cancer (96%) (p<0.001, ANOVA).
  • Serum MIF levels were low in patients with a normal mucosa (576 (82) pg/ml) but higher in patients with gastritis (2100 (349) pg/ml), intestinal metaplasia (4498 (253) pg/ml), and gastric cancer (9737 (1249) pg/ml) (p<0.001, ANOVA).
  • CONCLUSIONS: Epithelial and serum MIF expression was progressively increased in H pylori induced gastritis, intestinal metaplasia, and gastric cancer, suggesting that MIF is involved in gastric carcinogenesis and may be a valuable biomarker for the early detection of gastric cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Macrophage Migration-Inhibitory Factors / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic / metabolism. Chronic Disease. Disease Progression. Enzyme-Linked Immunosorbent Assay / methods. Female. Gastric Mucosa / pathology. Gastritis / metabolism. Gastritis / microbiology. Helicobacter Infections / complications. Helicobacter Infections / metabolism. Helicobacter pylori. Humans. Male. Metaplasia. Middle Aged. Neoplasm Proteins / blood. Neoplasm Proteins / metabolism. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):18100-6 [10364264.001]
  • [Cites] World J Gastroenterol. 2005 Jun 28;11(24):3767-71 [15968736.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 1999;139:1-32 [10453691.001]
  • [Cites] J Exp Med. 1999 Nov 15;190(10):1375-82 [10562313.001]
  • [Cites] Cytokine. 2000 Apr;12(4):309-14 [10805210.001]
  • [Cites] J Immunol. 2000 Jul 15;165(2):710-5 [10878343.001]
  • [Cites] Prostate. 2000 Sep 15;45(1):51-7 [10960842.001]
  • [Cites] Annu Rev Microbiol. 2000;54:615-40 [11018139.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4721-7 [11134134.001]
  • [Cites] J Immunol. 2001 Jan 15;166(2):747-53 [11145646.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Apr;15(4):505-11 [11284779.001]
  • [Cites] Cancer Lett. 2001 Oct 10;171(2):125-32 [11520595.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):619-30 [11522746.001]
  • [Cites] Oncogene. 2001 Nov 29;20(55):8009-18 [11753684.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):345-50 [11756671.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):667-80 [11875000.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Mar;16(3):521-6 [11876706.001]
  • [Cites] Microbes Infect. 2002 Apr;4(4):449-60 [11932196.001]
  • [Cites] Jpn J Cancer Res. 2002 Apr;93(4):389-96 [11985788.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):853-60 [12576459.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):243-7 [12584173.001]
  • [Cites] BMC Cancer. 2002 Dec 26;2:37 [12502432.001]
  • [Cites] Mod Pathol. 2003 May;16(5):491-504 [12748256.001]
  • [Cites] Int J Mol Med. 2003 Oct;12(4):633-41 [12964047.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G515-20 [15010360.001]
  • [Cites] J Infect Dis. 2004 Jul 15;190(2):293-302 [15216464.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1994 Jan;16(1):7-10 [8033753.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] J Mol Med (Berl). 1998 Mar;76(3-4):151-61 [9535548.001]
  • [Cites] Mol Med. 1998 Nov;4(11):707-14 [9932108.001]
  • [Cites] World J Gastroenterol. 2005 Apr 7;11(13):1946-50 [15800984.001]
  • [Cites] Mol Med. 1999 Mar;5(3):181-91 [10404515.001]
  • (PMID = 16488898.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Macrophage Migration-Inhibitory Factors; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC1856238
  •  go-up   go-down


40. Vannella L, Lahner E, Osborn J, Bordi C, Miglione M, Delle Fave G, Annibale B: Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther; 2010 May;31(9):1042-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis.
  • BACKGROUND: Atrophic gastritis, involving the gastric body mucosa, predisposes to gastric neoplastic lesions (GNL).
  • METHODS: A total of 300 patients with atrophic gastritis [205 women, aged 54 (18-78) years] underwent gastroscopy with six gastric antrum and body biopsies.
  • All patients had at least one follow-up gastroscopy/histology at an interval of at least 1 year after the atrophic gastritis diagnosis.
  • RESULTS: During a median follow-up of 4.3 (1-16.5) years, 15 GNL were detected in 14 of the 300 patients with atrophic gastritis: three were gastric cancer, whereas 12 were non-invasive neoplasia.
  • Cox-regression analysis identified the following risk factors: age over 50 years (HR 8.8, 95%CI 1.2-68.4), atrophic pangastritis (HR 4.5, 95% CI 1.5-14.1) and severe intestinal metaplasia in the gastric body (HR 4.0, 95% CI 1.3-11.8).
  • CONCLUSIONS: Atrophic pangastritis, severe body intestinal metaplasia and/or age over 50 years increase the risk for developing GNL in patients with atrophic gastritis.
  • [MeSH-major] Adenocarcinoma / pathology. Gastric Mucosa / pathology. Gastritis, Atrophic / pathology. Precancerous Conditions / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20175768.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


41. Filipec Kanizaj T, Katicić M, Presecki V, Gasparov S, Colić Cvrlje V, Kolarić B, Mrzljak A: Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases--cross-sectional study. Croat Med J; 2009 Apr;50(2):124-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the association of gastric histological and endoscopic findings in patients with Helicobacter pylori (H. pylori), according to presence of seropositivity to 12 bacterial virulence antigens.
  • Upper gastrointestinal endoscopy was performed, endoscopic diagnosis recorded, and 4 mucosal biopsy samples were obtained and assessed according to Updated Sydney protocol.
  • Thirty patients had gastric adenocarcinoma, 126 peptic ulcers, and 51 normal finding. p120 (CagA) seropositivity was significantly more often present in patients with higher activity grade in the antrum (P = 0.025), p30 in patients with greater inflammation in the antrum (P = 0.025) and the corpus (P = 0.010), p33 in patients with greater inflammation in the corpus (P = 0.050), and p19 (OMP) in patients with lower intestinal metaplasia grades in the corpus (P = 0.025).
  • Seroreactivity to all other bacterial proteins showed no association with the histological status of the stomach mucosa.
  • [MeSH-minor] Adult. Age Distribution. Aged. Confidence Intervals. Cross-Sectional Studies. Duodenal Neoplasms / immunology. Duodenal Neoplasms / microbiology. Duodenal Neoplasms / pathology. Duodenal Ulcer / immunology. Duodenal Ulcer / microbiology. Duodenal Ulcer / pathology. Endoscopy, Gastrointestinal. Female. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Peptic Ulcer / immunology. Peptic Ulcer / microbiology. Peptic Ulcer / pathology. Prognosis. Risk Assessment. Sensitivity and Specificity. Sex Distribution. Stomach Neoplasms / immunology. Stomach Neoplasms / microbiology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1994 May 1;179(5):1653-58 [8163943.001]
  • [Cites] J Clin Pathol. 1994 Mar;47(3):227-31 [8163693.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] J Clin Microbiol. 1995 Jun;33(6):1496-500 [7650174.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1995 Jun;7(6):533-6 [7552635.001]
  • [Cites] Clin Diagn Lab Immunol. 1994 May;1(3):310-7 [7496968.001]
  • [Cites] Lab Invest. 1995 Dec;73(6):760-70 [8558837.001]
  • [Cites] Infect Immun. 1996 Apr;64(4):1166-72 [8606074.001]
  • [Cites] J Infect Dis. 1996 May;173(5):1171-5 [8627069.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):1-5 [8690507.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2829-33 [8698518.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] J Clin Pathol. 1996 Oct;49(10):829-32 [8943750.001]
  • [Cites] J Clin Invest. 1997 Aug 15;100(4):759-62 [9259572.001]
  • [Cites] Am J Gastroenterol. 1998 Mar;93(3):375-9 [9517643.001]
  • [Cites] J Clin Microbiol. 1998 Apr;36(4):931-6 [9542911.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):55-61 [9577374.001]
  • [Cites] BMJ. 1998 May 16;316(7143):1507-10 [9582144.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1517-21 [10364017.001]
  • [Cites] J Clin Microbiol. 1999 Jul;37(7):2306-11 [10364602.001]
  • [Cites] J Clin Microbiol. 1999 Jul;37(7):2348-9 [10364612.001]
  • [Cites] J Clin Microbiol. 1999 Jun;37(6):2113-4 [10383258.001]
  • [Cites] Clin Diagn Lab Immunol. 1999 Jul;6(4):489-93 [10391848.001]
  • [Cites] Int J Med Microbiol. 2006 Aug;296(4-5):223-8 [16600680.001]
  • [Cites] APMIS. 2008 Jun;116(6):465-76 [18754320.001]
  • [Cites] Scand J Gastroenterol. 1999 Oct;34(10):981-6 [10563667.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1308-15 [10579972.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):274-9 [10640957.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1530-5 [10738209.001]
  • [Cites] FEMS Immunol Med Microbiol. 2000 Jun;28(2):139-41 [10799804.001]
  • [Cites] Helicobacter. 2000;5 Suppl 1:S3-9; discussion S27-31 [10828748.001]
  • [Cites] Croat Med J. 2000 Jun;41(2):159-62 [10853044.001]
  • [Cites] Res Microbiol. 2000 Apr;151(3):191-200 [10865946.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):981-5 [11008919.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):647-54 [11159201.001]
  • [Cites] Scand J Gastroenterol. 2001 Apr;36(4):351-5 [11336157.001]
  • [Cites] Lijec Vjesn. 2002 Sep;124 Suppl 1:5-9 [12592807.001]
  • [Cites] Scand J Gastroenterol. 2004 Mar;39(3):222-6 [15074390.001]
  • [Cites] Croat Med J. 2004 Oct;45(5):592-8 [15495287.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5791-5 [8516329.001]
  • [Cites] Infect Immun. 1994 May;62(5):1557-65 [8168917.001]
  • (PMID = 19399945.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antigens, Bacterial
  • [Other-IDs] NLM/ PMC2681059
  •  go-up   go-down


42. Schiffman SC, Li Y, Dryden G, Li X, Martin RC: Positive correlation of image analysis by mini-endoscopy with micro-PET scan and histology in rats after esophagoduodenal anastomosis. Surg Endosc; 2010 Nov;24(11):2835-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In previous studies we have used micro-PET scan to analyze the esophageal adenocarcinoma (EAC) transformation in an intact rat model of esophagoduodenal anastomosis (EDA), in which intestinal metaplasia and EAC were reproduced successfully.
  • RESULTS: The endoscope provided visualization of the entire esophageal tract and upper stomach, with the smallest detectable lesion being 0.5 mm in diameter.
  • CONCLUSIONS: The new mini-endoscope constitutes a practical and reliable tool for diagnosis and regular follow-up of the esophagus in rats.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Esophagus. 2007;20(5):372-8 [17760649.001]
  • [Cites] Gastroenterology. 1970 Feb;58(2):163-74 [5413015.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5176-82 [17785574.001]
  • [Cites] Dig Dis Sci. 2006 Mar;51(3):527-32 [16614962.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1801-8 [10469627.001]
  • [Cites] Appl Spectrosc. 2007 Jun;61(6):579-84 [17650367.001]
  • [Cites] J Surg Res. 2000 Feb;88(2):120-4 [10644476.001]
  • [Cites] N Engl J Med. 1999 Nov 4;341(19):1439 [10547407.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):257-63 [10657966.001]
  • [Cites] Dis Esophagus. 2009;22(4):323-30 [19473210.001]
  • [Cites] J Surg Res. 2006 Oct;135(2):337-44 [16926029.001]
  • [Cites] J Surg Res. 2005 Nov;129(1):107-13 [15921698.001]
  • [Cites] Curr Opin Gastroenterol. 1999 Jul;15(4):352-8 [17023971.001]
  • [Cites] Cancer Invest. 2008 Apr-May;26(3):278-85 [18317969.001]
  • [Cites] Ann Surg Oncol. 2007 Jul;14(7):2045-55 [17473952.001]
  • (PMID = 20440518.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA127801-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


43. Sargan I, Motoc A, Vaida MA, Bolintineanu S, Vîscu S: Anatomic and pathological aspects in the pathology of malignant gastric tumors. Rom J Morphol Embryol; 2006;47(2):163-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomic and pathological aspects in the pathology of malignant gastric tumors.
  • Efforts in perfecting the methods of early diagnosis, in trying to assess premalignant conditions, and in properly staging malignant tumors are still in trend.
  • The geographic area around Timişoara (Banat Region) is situated on the first place in the country as far as the gastric location of cancer is concerned.
  • The authors aimed to deal with the initial stage in the development of gastric cancer, a stage which has been oncologically termed "precancerous damage", and with the neoplastic invasion of the gastric wall.
  • The present paper is based on the 1995-2005 statistics of the IInd Surgical Department of the Timişoara County Hospital, the study group consisting of 802 patients admitted for gastric disorders, 522 of which being later diagnosed with a tumoral pathology.
  • The age for gastric tumoral pathology ranged between 36-88 years in females, and 31-87 years in males.
  • Most gastric carcinomas are adenocarcinoma, 404 (90%) cases--could be classified as follows: 167 cases of tubular adenocarcinoma; 39 cases of papillary adenocarcinoma; 24 cases of mucinous or colloid adenocarcinoma; 141 "signet ring"-cell carcinoma; 33 cases of undifferentiated carcinoma.
  • Attention should be given to precancerous conditions; there was a large number of premalignant or potentially malignant gastric damage: atrophic chronic gastritis (54 cases), intestinal metaplasia (104 cases), and gastric dysplasia (104 cases).
  • [MeSH-major] Precancerous Conditions / pathology. Stomach / anatomy & histology. Stomach / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Biopsy. Female. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17106525.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


44. Huang MF, Zhu YQ, Chen ZF, Xiao J, Huang X, Xiong YY, Yang GF: Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancer. World J Gastroenterol; 2005 May 21;11(19):2975-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancer.
  • AIM: To elucidate the role and alterations of syndecan-1 and E-cadherin expression in different cellular phenotypes of differentiated-type gastric cancers (DGCs).
  • Based on immunohistochemistry, DGCs and their surrounding mucosa were divided into four types: gastric type (G-type), ordinary type (O-type), complete-intestinal type (CI-type), and null type (N-type).
  • In addition, syndecan-1 expression was significantly reduced in DGCs comprised partly of poorly differentiated adenocarcinoma or signet-ring cell carcinoma, compared to DGCs demonstrating papillary and/or tubular adenocarcinoma (P<0.05).
  • G-type intestinal metaplasia (IM) surrounding the tumors was observed in 23.8% of G-type, 4.9% of O-type, and 6.7% of CI-type cancers (P<0.05; G-type vs O-type).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cadherins / metabolism. Membrane Glycoproteins / metabolism. Proteoglycans / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Cell Differentiation. Early Diagnosis. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Syndecan-1. Syndecans

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Gastroenterol. 2008 Apr 14;14(14):2290-1 [18551811.001]
  • (PMID = 15902740.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans
  • [Other-IDs] NLM/ PMC4305671
  •  go-up   go-down


45. Kandulski A, Selgrad M, Malfertheiner P: Helicobacter pylori infection: a clinical overview. Dig Liver Dis; 2008 Aug;40(8):619-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Helicobcater pylori colonizes the stomach of more than half of the world's population, and the infection continues to play a key role in the pathogenesis of a number of gastroduodenal diseases.
  • Colonization of the gastric mucosa with Helicobcater pylori results in the development of chronic gastritis in all infected individuals and in a subset of patients chronic gastritis progresses to complications (i.e. ulcer disease, gastric neoplasias, some distinct extragastric disorders).
  • Helicobcater pylori eradication for gastric cancer prevention has been suggested by preclinical research and clinical trials, showing even reversibility of precancerous lesions (atrophic gastritis and intestinal metaplasia) after Helicobcater pylori eradication.
  • [MeSH-major] Helicobacter Infections / diagnosis. Helicobacter Infections / microbiology. Helicobacter pylori
  • [MeSH-minor] Adenocarcinoma / microbiology. Adenocarcinoma / prevention & control. Anemia, Iron-Deficiency / microbiology. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Asthma / microbiology. Dyspepsia / microbiology. Gastroesophageal Reflux / microbiology. Humans. Hypersensitivity, Immediate / microbiology. Lymphoma, B-Cell, Marginal Zone / microbiology. Peptic Ulcer / chemically induced. Peptic Ulcer / diagnosis. Peptic Ulcer / drug therapy. Peptic Ulcer / microbiology. Purpura, Thrombocytopenic, Idiopathic / microbiology. Stomach Neoplasms / microbiology. Stomach Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396114.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  • [Number-of-references] 80
  •  go-up   go-down


46. Mihailovici MS, Danciu M, Ivan L, Ferariu D: Early gastric carcinoma diagnosed on endobiopsic and surgical specimens. Rom J Morphol Embryol; 2006;47(3):235-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early gastric carcinoma diagnosed on endobiopsic and surgical specimens.
  • Early gastric carcinoma (EGC) is difficult to diagnose without a screening program.
  • AIMS: In this study, we reveal the importance of endobiopsy in EGC diagnosis.
  • MATERIAL AND METHODS: We examined multiple gastric endobiopsies from 1,201 patients with or without symptoms and endoscopical aspect for gastric carcinoma.
  • We used Laurén histological classification with two main types of gastric carcinoma: intestinal and diffuse.
  • RESULTS: From 1,201 gastric endobiopsies, we diagnosed gastric carcinoma in 257 patients (21.3%) and only four of them were EGCs, although their endoscopical examination was negative for gastric tumor.
  • The additional endobiopsies fragments presented chronic atrophic gastritis with H. pylori infection, intestinal metaplasia and dysplasia.
  • CONCLUSIONS: EGC had an incidence of 0.34%, which is very low because the lack of an endoscopical screening program favors the diagnosis of gastric cancer in advanced stages.
  • Both histological types--intestinal and diffuse, were present in EGC, associated with H. pylori chronic gastritis, intestinal metaplasia and dysplasia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17308681.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


47. Mabrut JY, Collard JM, Baulieux J: [Duodenogastric and gastroesophageal bile reflux]. J Chir (Paris); 2006 Nov-Dec;143(6):355-65
Hazardous Substances Data Bank. CISAPRIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study reviews current data regarding duodenogastric and gastroesophageal bile reflux-pathophysiology, clinical presentation, methods of diagnosis (namely, 24-hour intraluminal bile monitoring) and therapeutic management.
  • Duodenogastric reflux (DGR) consists of retrograde passage of alkaline duodenal contents into the stomach; it may occur due to antroduodenal motility disorder (primary DGR) or may arise following surgical alteration of gastoduodenal anatomy or because of biliary pathology (secondary DGR).
  • In patients with concomitant gastroesophageal reflux, the backwash of duodenal content into the lower esophagus can cause mixed (alkaline and acid) reflux esophagitis, and lead, in turn, to esophageal mucosal damage such as Barrett's metaplasia and adenocarcinoma.
  • Proton pump inhibitors decrease the upstream effects of DGR on the esophagus by decreasing the volume of secretions; promotility agents diminish gastric exposure to duodenal secretions by improving gastric emptying.
  • [MeSH-minor] Anion Exchange Resins / therapeutic use. Anti-Ulcer Agents / therapeutic use. Barrett Esophagus / etiology. Barrett Esophagus / physiopathology. Bile Acids and Salts / analysis. Cholecystectomy / adverse effects. Cholestyramine Resin / therapeutic use. Chromatography, High Pressure Liquid. Cisapride / therapeutic use. Duodenum / surgery. Esophagitis, Peptic / etiology. Esophagitis, Peptic / physiopathology. Gastric Acidity Determination. Gastrointestinal Agents / therapeutic use. Gastroplasty. Helicobacter Infections / complications. Helicobacter pylori. Humans. Hydrogen-Ion Concentration. Proton Pump Inhibitors. Risk Factors. Stomach Neoplasms / etiology. Sucralfate / therapeutic use

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • Hazardous Substances Data Bank. CHOLESTYRAMINE RESIN .
  • Hazardous Substances Data Bank. SUCRALFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285081.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anion Exchange Resins; 0 / Anti-Ulcer Agents; 0 / Bile Acids and Salts; 0 / Gastrointestinal Agents; 0 / Proton Pump Inhibitors; 11041-12-6 / Cholestyramine Resin; 54182-58-0 / Sucralfate; UVL329170W / Cisapride
  • [Number-of-references] 182
  •  go-up   go-down


48. Da CL, Xin Y, Zhao J, Luo XD: Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol; 2009 Aug 28;15(32):4055-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions.
  • AIM: To analyze the differences and relevance of Yes-associated protein (YAP) and survivin, and to explore the correlation and significance of their expression in gastric carcinoma and precancerous lesions.
  • METHODS: The PV9000 immunohistochemical method was used to detect the expression of YAP and survivin in 98 cases of normal gastric mucosa, 58 intestinal metaplasia (IM), 32 dysplasia and 98 gastric carcinoma.
  • RESULTS: The positive rates of YAP in dysplasia (37.5%) and gastric carcinoma (48.0%) were significantly higher than that in normal gastric mucosa (13.3%), P < 0.01.
  • The positive rates of survivin in IM (53.4%), dysplasia (59.4%) and gastric carcinoma (65.3%) were significantly higher than in normal gastric mucosa (11.2%), P < 0.01.
  • Survivin expression gradually increased from 41.7% in well differentiated adenocarcinoma through 58.3% in moderately differentiated adenocarcinoma to 75.6% in poorly differentiated adenocarcinoma, with significant Rank correlation, r(k) = 0.279, P < 0.01.
  • The positive rate of survivin in gastric carcinoma of diffused type (74.6%) was significantly higher than that in intestinal type (51.3%), P < 0.05.
  • In gastric carcinoma with lymph node metastasis (76.9%), the positive rate of survivin was significantly higher than that in the group without lymph node metastasis (41.2%), P < 0.01.
  • In 98 cases of gastric carcinoma, the expression of YAP and of survivin were positively correlated, r(k) = 0.246, P < 0.01.
  • Detecting both markers together may help in early diagnosis of gastric carcinoma.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Carcinoma / metabolism. Gene Expression Regulation, Neoplastic. Microtubule-Associated Proteins / metabolism. Phosphoproteins / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Aged. Apoptosis. Female. Gastric Mucosa. Gene Expression Profiling. Humans. Inhibitor of Apoptosis Proteins. Intestines / metabolism. Lymphatic Metastasis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1999 Dec;23(4):387-8 [10581018.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Jun 19;384(1):114-9 [19393221.001]
  • [Cites] Acta Obstet Gynecol Scand. 2002 Feb;81(2):162-7 [11942908.001]
  • [Cites] Mol Cell. 2003 Jan;11(1):11-23 [12535517.001]
  • [Cites] Oncogene. 1994 Aug;9(8):2145-52 [8035999.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Biochemistry. 2005 Jan 11;44(1):11-7 [15628841.001]
  • [Cites] Cell. 2005 Mar 11;120(5):675-85 [15766530.001]
  • [Cites] Prostate. 2005 Aug 1;64(3):293-302 [15754318.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 19;334(1):207-12 [15993841.001]
  • [Cites] Cell. 2006 Jan 27;124(2):267-73 [16439203.001]
  • [Cites] Mol Biol Cell. 2006 Mar;17(3):1483-93 [16407408.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12405-10 [16894141.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2337-47 [16985068.001]
  • [Cites] Cell. 2007 Sep 21;130(6):1120-33 [17889654.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2747-61 [17974916.001]
  • [Cites] Int J Gastrointest Cancer. 2006;37(4):103-9 [18175224.001]
  • [Cites] Mol Cell. 2008 Dec 26;32(6):803-14 [19111660.001]
  • [Cites] Biochem Cell Biol. 2009 Feb;87(1):77-91 [19234525.001]
  • [Cites] Exp Cell Res. 2002 Apr 15;275(1):44-53 [11925104.001]
  • (PMID = 19705503.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Phosphoproteins; 0 / YAP1 (Yes-associated) protein, human
  • [Other-IDs] NLM/ PMC2731958
  •  go-up   go-down


49. Griffiths EA, Pritchard SA, Valentine HR, Whitchelo N, Bishop PW, Ebert MP, Price PM, Welch IM, West CM: Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer; 2007 Jan 15;96(1):95-103
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas.
  • Hypoxia-inducible factor-1 (HIF-1)alpha expression was studied in the gastric carcinogenesis sequence and as a prognostic factor in surgically resected gastric and gastro-oesophageal junction tumours.
  • Protein expression was examined using immunohistochemistry on formalin-fixed biopsies of normal mucosa (n=20), Helicobacter pylori associated gastritis (n=24), intestinal metaplasia (n=24), dysplasia (n=12) and intestinal (n=19) and diffuse (n=21) adenocarcinoma.
  • The relationship between HIF-1alpha expression and prognosis was assessed in resection specimens from 177 patients with gastric and gastro-oesophageal junction adenocarcinoma.
  • Hypoxia-inducible factor-1alpha expression was not observed in normal gastric mucosa but increased in density (P<0.01) and intensity (P<0.01) with progression from H. pylori-associated gastritis, intestinal metaplasia, dysplasia to adenocarcinoma.
  • The results suggest HIF-1alpha is involved in gastric carcinogenesis and disease progression, but is only a weak prognostic factor for survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2005 Mar 18;17(6):793-803 [15780936.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):881-90 [11556841.001]
  • [Cites] Jpn J Clin Oncol. 2005 Apr;35(4):207-13 [15845570.001]
  • [Cites] Gut. 2005 Jul;54(7):920-7 [15951534.001]
  • [Cites] J Pathol. 2005 Nov;207(3):277-84 [16184519.001]
  • [Cites] Eur J Cancer. 2005 Dec;41(18):2792-805 [16290133.001]
  • [Cites] Gastric Cancer. 2006;9(1):44-9 [16557436.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):149-54 [16847924.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5112-7 [16951228.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5779-88 [11593383.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):28-37 [11902583.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2493-7 [11980639.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):854-61 [12095550.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):889-92 [12213583.001]
  • [Cites] J Histochem Cytochem. 2003 Jan;51(1):129-32 [12502763.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):433-40 [12538497.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):258-70 [12619111.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 2;95(7):516-25 [12671019.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1789-806 [12759237.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):797-802 [12792726.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Jul;18 Suppl 1:90-8 [12925145.001]
  • [Cites] Mol Biol Cell. 2003 Aug;14(8):3470-81 [12925778.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1042-7 [12966423.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Melanoma Res. 2003 Oct;13(5):493-501 [14512791.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):88-93 [15068831.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):838-44 [15170665.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):946-56 [15199114.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Aug 1;20(3):261-70 [15274662.001]
  • [Cites] Gut. 2004 Sep;53(9):1217-9 [15306570.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5876-81 [15313932.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1009-14 [15452150.001]
  • [Cites] Ann Med. 2004;36(7):530-9 [15513303.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3238-43 [8764115.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Nature. 1998 Jul 30;394(6692):485-90 [9697772.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):370-4 [9708203.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Eur J Cancer Prev. 1998 Dec;7(6):439-47 [9926291.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Cell Mol Med. 2004 Oct-Dec;8(4):423-31 [15601571.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8405-12 [15623619.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8554-60 [15623639.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):172-7 [15677538.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1129-35 [15709180.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1111-5 [10836997.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3A):1527-33 [10928066.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2911-6 [11306467.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1661-8 [11410504.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 1;93(15):1175-7 [11481392.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):261-6 [11556755.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3299-306 [15833863.001]
  • (PMID = 17179985.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  • [Other-IDs] NLM/ PMC2360219
  •  go-up   go-down


50. González CA, Pardo ML, Liso JM, Alonso P, Bonet C, Garcia RM, Sala N, Capella G, Sanz-Anquela JM: Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Int J Cancer; 2010 Dec 1;127(11):2654-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain.
  • There are no established criteria to classify patients into high or low risk of progressing to gastric cancer (GC).
  • The aim of the study was to identify predictors of GC occurrence among patients with gastric preneoplastic lesions.
  • The study included 478 patients who underwent gastric biopsy in 1988-1994 with diagnoses of normal mucosa, nonatrophic gastritis (NAG), non-metaplastic multifocal atrophic gastritis (MAG) and complete or incomplete intestinal metaplasia (IM) and who accepted to undergo a new biopsy during 2005-2007 or had an event during follow up.
  • Inter- and intra-observer variability of histological diagnosis was assessed.
  • Out the 21 adenocarcinomas, 16 had an incomplete IM in the baseline diagnosis.
  • Incomplete IM (HR 11.3; 95% CI 3.8-33.9) and a family history of GC (HR 6.1; 95% CI 1.7-22.4) were the strongest risk factors for gastric adenocarcinoma.
  • [MeSH-major] Precancerous Conditions / epidemiology. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adult. Aged. Disease Progression. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Proportional Hazards Models. Prospective Studies. Retrospective Studies. Risk Factors. Spain / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20178099.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Long KB, Hornick JL: SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract. Hum Pathol; 2009 Dec;40(12):1768-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SOX2 is a high-mobility group box embryonic stem cell transcription factor that is expressed in the developing foregut and normal gastric epithelium and is downregulated in intestinal metaplasia of the stomach and esophagus.
  • [MeSH-minor] Adenocarcinoma / metabolism. Diagnosis, Differential. Homeodomain Proteins / biosynthesis. Humans. Immunohistochemistry. Keratin-5 / biosynthesis. Keratin-6 / biosynthesis. Membrane Proteins / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716157.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / CKAP4 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-5; 0 / Keratin-6; 0 / Membrane Proteins; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors
  •  go-up   go-down


52. Park JH, Lee BL, Yoon J, Kim J, Kim MA, Yang HK, Kim WH: Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum Pathol; 2010 Dec;41(12):1664-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer.
  • Because the clinical implications of focal adhesion kinase overexpression in gastric cancer have been inconsistent, we extended previous studies and evaluated focal adhesion kinase gene amplification as well as its protein expression.
  • Immunohistochemical tissue array analysis showed that focal adhesion kinase immunoreactivity was present in both the cytoplasm and membrane of gastric cancer cells.
  • Regarding focal adhesion kinase gene amplification, fluorescence in situ hybridization analysis showed focal adhesion kinase gene amplification in 34 (8.9%) of 384 gastric cancer specimens, whereas there was no amplification in any case of atrophy, intestinal metaplasia, or adenoma/dysplasia.
  • In conclusion, our results showed that either focal adhesion kinase protein expression or focal adhesion kinase gene amplification was significantly correlated with cancer progression and poor prognosis in gastric cancer.
  • Thus, focal adhesion kinase gene amplification could supplement its protein expression for the diagnosis and treatment of gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Focal Adhesion Kinase 1 / genetics. Gene Amplification. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20869748.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / PTK2 protein, human
  •  go-up   go-down






Advertisement